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ABSTRACT

EXPLOITATION OF COSTIMULATORY SA-4-1BBL IN THE DEVELOPMENT OF
THERAPEUTIC CANCER VACCINES
Abhishek K. Srivastava
March 31, 2011
Cancer accounts for nearly one-quarter of deaths in the United States, exceeded
only by heart diseases. Despite the development of various strategies to treat cancer, it
remains one of the most deadly diseases worldwide due to the limited effects of
treatments available. The limited efficacy of these current treatment modalities, such as
surgery, radiotherapy, and chemotherapy, are often due to their association with adverse
side effects arising from lack of specificity for tumors, and most importantly their failure
of eliminating residual and micro-metastatic tumors, which can lead to recurrences.
Therefore, there is a dire need to develop tumor-specific therapies that not only eliminate
primary tumors, but also micro-metastasis and prevent recurrences. In this regard,
therapeutic cancer vaccines based on tumor-associated antigens (TAAs) has evolved as a
promising approach due to their safety profile, ease of production, storage, transportation,
administration to a broad patient population and most importantly establishment and/or
maintenance of long-term immunological memory critical for the control of recurrences,
a major cause of cancer death. However, despite theoretical promise, development of
therapeutic cancer vaccines has been facing numerous set-backs mostly due to the weak
immunogenicity of TAAs, tolerance to self-TAAs and various immune evasion
vi

mechanisms employed by progressing tumors. Therefore, we hypothesized that use of
natural costimulatory ligands of TNF family as adjuvant may overcome these limitations
due to their effect on cells of innate, adaptive, and regulatory immunity without any sign
of toxicity. The tumor necrosis factor receptor (TNFR)/TNF superfamily represents a
crucial group of costimulatory receptor/ligands as most of the receptors of this family are
inducibly expressed on various immune cells. Costimulatory receptors that are inducibly
expressed or upregulated on activated T cells may serve as preferred targets for
immunomodulation due to their potential to selectively target antigen-experienced T cells
for expansion, survival, and establishment oflong-term immunological memory. Among
these family members, 4-1BB/4-1BBL signaling has recently been much appreciated as
its signaling provides the essential survival signals, particularly in CD8+ T cells. 4-1BB
signaling into T cells allows CD8+ T cell expansion, cytokine production, development of
CTL effector function, and prevention of apoptotic cell death by up-regulating antiapoptotic Bcl-xL and Bcl-2 molecules. As the aim of tumor immunotherapy is to generate
long-lasting immune response, particularly CD8+ T cell specific response, for the
destruction of tumor cells, in this project, we focused on the utilization of 4-1 BBL either
alone or in combination with other immunomodulators, as a component of TAA-based
subunit vaccines and tested its efficacy in preclinical mice tumor models.
First, we report that a single immunization with a therapeutic vaccine formulation
containing novel form of soluble SA-4-1BBL, and survivin (SVN), a bona fide self
antigen, resulted into the eradication of SVN-expressing 3LL tumors in 75% of mice in
the absence of autoimmunity. The efficacy of vaccine was further improved to complete
tumor eradication with an additional vaccination 6 days after the first vaccination. CD8+
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T cells and NK cells effector function was found to be critical for the efficacy of vaccine,
but not the CD4 + T cells.
Next, we tested the vaccine formulation containing combination of SA-4-IBBL
and toll-like receptor 4 agonist monophosphoryllipid A (MPL) with distinct mechanisms
of action as a novel adjuvant system. A single immunization with both adjuvants and
HPV E7 protein resulted in eradication of 100% of E7 expressing TC-I tumors.
Combined adjuvants had better therapeutic efficacy over the individual adjuvants, while
SA-4-IBBL monotherapy outperformed MPL, 80% vs. 50%. Similarly, a single
vaccination with SVN resulted in control/eradication of established 3LL pulmonary
metastases that was further improved by a booster injection. The therapeutic efficacy of
combined adjuvants as well as SA-4-IBBL as monotherapy was achieved in the absence
of detectable toxicity and correlated with enhanced CD8+ T cell function and increased
intratumoral CD8+ T effector/CD4+FoxP3+ T regulatory cell ratio. In marked contrast,
vaccination with MPL as monotherapy resulted in an unfavorable intratumoral CD8+ T
effector/CD4+FoxP3+ T regulatory cell ratio that played a definitive role in vaccine
efficacy. Depletion of T regulatory cells improved MPL efficacy to 100%, whereas
elimination of CD8+ T cells totally abrogated the efficacy of combined adjuvants.
In last, we report that combination of SA-4-IBBL and SA-OX40L, another
member of TNF ligand family, was also able to eradicate TC-I tumors in 100% of mice.
This efficacy was mainly dependent on CD8+ T cells as depletion of these cells
completely abrogated the efficacy. Importantly, combination of these two ligands was
also able to eradicate a 3-4 mm established tumors in 50% of mice.
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Taken together, these data provide important mechanistic insight into the mode of
action of SA-4-1BBL alone or in combination either MPL or SA-OX40L adjuvants and
demonstrate its utility as a novel adjuvant system for the development of therapeutic
TAA-based subunit cancer vaccines with significant clinical implications. These data also
shed lights into the mode of action of MPL and SA-OX40L as a part of vaccine adjuvant
systems and set the stage for their utilization in the development of new vaccine
strategies.
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CHAPTERl
INTRODUCTION

Cancer is the one of the leading causes of death in the United States and
worldwide. Despite growing efforts in the development of various strategies to treat
cancer, it remains one of the most deadly diseases with the limited effects of treatments
available. The limited efficacy of these current treatment modalities, such as surgery,
radiotherapy, and chemotherapy, are often due to their association with adverse side
effects arising from lack of specificity for tumors, and most importantly their failure of
eliminating residual and micro-metastatic tumors, which can lead to recurrences (1).
Therefore, there is a dire need to develop tumor-specific therapies that not only eliminate
primary tumors, but also micro-metastasis and prevent recurrences. In this scenario,
therapeutic cancer vaccines based on tumor associated antigens (TAAs) are preferred
alternatives to conventional treatments primarily because of their safety profile and
generation of long-term immunological memory critical for the control of recurrences,
which are major cause of death from cancer.
The theory of cancer immune-surveillance suggests that the immune system has
the ability to recognize precursors of cancer and, in most cases, mount an effective
response to destroy these precursors before they become clinically apparent (2). This
notion is supported by observations that mice lacking essential components of the innate
or adaptive immune responses are susceptible to the development of spontaneous or
1

designed to enhance the ability of immune system can reduce the development of
malignant disease in animal models. If immune-surveillance plays a key role
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controlling the tumor progreSSIOn, then one would expect the patients with premalignancy will mount vigorous immune responses. There are, indeed, scientific
evidences indicating that this might be the case. Patients with monoclonal gammopathy, a
pre-malignant disease, mount strong T cell responses against autologous pre-malignant B
cells, whereas no responses are found in patients with malignant multiple myeloma (3).
Additionally, breast cancer-associated proteins mucin-l and HER2 specific CD8+ T cells
from breast cancer patients are able to regress autologous human tumors that have been
transplanted into immunodeficient non-obese diabetic mice (4). These studies suggest
that, although tumors induce at least transient immune responses, cancer can still
develop. This indicate that such cellular immune responses are either too low to prevent
the tumor progression or evaded by tumor cells as its safety mechanism. Therefore, the
development of therapeutic cancer vaccines capable of generating a robust tumor-specific
immunity may serve as a promising tool for cancer treatment. However, despite
demonstrated efficacy in test tubes and experimental animals, efforts to harness the
immune system to fight cancer using cancer vaccines have been challenging for decades
and have largely ended in failure. This may be due to the weak antigenic nature of self
tumor-associated antigens (TAAs), both central and peripheral tolerogenic mechanisms,
and various immune evasion mechanisms employed by the progressing tumors. These
limitations can potentially be overcome by developing vaccine formulations including
adjuvants that not only generate potent immune responses against TAAs with long-term
immunological memory, but also overcome various immune evasion mechanisms.

2

Cancer Vaccines:
The development of successful vaccines against infectious diseases is one of
medicine's most important accomplishments. Their influence on majority of human
population is aptly expressed by vaccinologist Stanley Plotkin when he says: "The impact
of vaccination on human health of the world's peoples is hard to exaggerate. With the
exception of safe water, no other modality, not even antibiotics, has had such a major
effect on mortality reduction and population growth" (5). The success of these vaccines
primarily lies in their ability to induce long-lived antibody responses that protect against
highly immunogenic bacteria and viruses. However, development of therapeutic vaccines
against cancer faces a much greater challenges because their target often consist of
tumor-associated self-antigens (TAAs), which are poorly immunogenic and often
heterogeneously expressed by genetically unstable tumor cells that undergo mutations
and frequently suppress immune responses at the cellular level in the tumor
microenvironment. Therefore, despite several encouraging advances in the area of
vaccinology, cancer is still a major public health problem worldwide, and requires new
strategies for the development of potent vaccines to optimize patient outcomes.
In the last several years, numerous strategies such as cell-based vaccines, DNAor RNA-based vaccines, protein/peptide vaccines, and vector-based vaccines, have been
employed to overcome this weak immunogenic response against TAAs (6). The idea of
using these first generation cancer vaccines is primarily based on their ability to activate
antigen-presenting cells (APCs) and stimulate antigen-specific cytotoxic T lymphocyte
(CTL)-mediated immune response. In this context, dendritic cells (DCs), the most
effective APCs, have been targeted to enhance their ability to activate T cells. In the last
3

several years, a variety of strategies have been employed to "instruct" DCs to induce
robust immune responses against tumor antigens, thus breaking immune tolerance. The
main focus of these strategies revolve around the efficient antigen-loading that include, i)
infecting DCs with viral, bacterial, or yeast vectors, ii) pulsing DCs with proteins or
peptides, iii) loading DCs with whole tumor cells or lysates, and iv) transfecting DCs
with DNA or RNA.
Viral, Bacterial and Yeast Vectors-based Vaccines:

The common vectors used in the development of therapeutic cancer vaccines
include virus, bacterial and yeast vectors. These vectors are used to deliver recombinant
genes such as genes expressing TAAs, costimulatory molecules, and cytokines into
APCs. As a result, these recombinant vectors may induce increased immune response
against the gene of interest that has been inserted into the vector. Poxvirus vectors
(vaccinia virus prototype) are among the most utilized vectors for the development of
vaccines. The advantage of using these vectors is that they replicate within the cytoplasm
of infected cells, which is important for the safe use of this vector as recombinant
vaccines, and no genetic sequence from the virus will be inserted into the host genome.
PSA-TRICOM, a poxvirus-based vaccine has been evaluated in 2 phase II clinical
trials in patients with metastatic hormone-refractory prostate cancer (7). In the first trial,
vaccinated patients had a greater 3-year overall survival and improved in median overall
survival of 8.5 months when compared to the placebo controls. In the second phase II
clinical trial at National Cancer Institute (NCI), patients vaccinated with PSA-TRICOM
had improved median overall survival of 9.2 months. This study also suggested that
Tregs playa significant role in the modulation of antitumor immunity. PANVAC-VF,
4

another poxvirus-based vaccine, was also tested in a phase III clinical trial in patients
with advanced pancreatic cancer (8). The vaccine is also under evaluation in several other
CEA- or MUCl-expressing carcinomas. A pilot study at NCI has shown the tolerance of
PANVAC-VF in 25 patients with metastatic carcinomas. The vaccine generated an
antigen specific T effector response in 3/8 patients measured by ELISPOT, tetramer, and
intracellular IFN-y staining (9).
In the last several years, a variety of different bacterial and yeast vectors have also
been used for vaccine development. Among these, E coli, Salmonella, Yersinia, Shigella,
Listeria monocytogenes, and Sccharomyces cerevisiae are the most investigated as

vaccine vectors. The rationale for utilization of these microbes-based vectors as delivery
vehicle for TAAs is primarily based on their ability to induce pro-inflammatory responses
via interaction of pathogen-associated molecular patterns (PAMPs) with pattern-

recognition receptors (PRRs) expressed on APCs. These interactions are the key
controller of the activation of innate and adaptive immune responses (10). Most
importantly, by the utilization of genetic engineering and efficient fermentation
technologies, these vectors can be used for the production of large-scale, cost effective
antitumor vaccines. Although, viral and bacterial based vaccines showed some
advantages, these systems have various limitations, such as requiring mitotic cell division
for transduction, low maintenance of trans gene expression, and immune elimination of
infected cells that limits gene expression in vivo. In addition, there are safety concerns
arising from mutations in the transferred viral genome leading to virulent forms (11).
Protein or Peptide-based vaccines:

5

The use of proteins or peptides has long been an attractive approach to stimulate
an effective immune response against variety of cancers. This strategy covers a broad
spectrum of possibilities of utilizing single protein or combination of proteins (12), fusion
proteins, peptides, and agonist peptides (13, 14). The major advantages of using these
protein or epitope-based strategies are their ease of production, storage, transportation
and low cost.
Recently, in the preclinical settings, we have demonstrated that both E7-peptide
and E7 whole protein in combination with SA-4-IBBL, a costimulatory chimeric
adjuvant based vaccine successfully eradicated the established TC-l tumors in over 70%
of mice (15, 16). Survivin (SVN) protein based vaccine has also shown a promising
outcome in eradicating the tumors in both transplantable and pulmonary lung metastases
tumor models. In the clinical settings, Oncophage, a HSP gp96 peptide-based vaccine has
been tested in two phase III clinical trials against melanoma and renal cell carcinoma
(RCC) (17, 18). Although, in the first phase III clinical trials in melanoma patients
vaccine was able to provide survival benefits after 10 or more vaccinations, but in the
second clinical trial in RCC patients, no difference in recurrence-free survival or overall
survival was observed between patients receiving Oncophage versus no treatment.
Stimuvax, a MUC-I peptide-based vaccine which widely expressed on many tumors
(lung, breast, prostate, colorectal), has also been evaluated in phase II B clinical trial in
non-small cell lung cancer (NSCLC) (19) and showed positive signs of vaccine efficacy.
Based on these data, Merck is currently conducting three large phase III clinical trials of
Stimuvax.

6

Despite some promising clinical outcomes, use of specific proteins or peptides for
the development of therapeutic vaccines clearly requires a careful selection of targeted
TAAs, and their epitopes along with the ability to understand their structural and
functional characteristics. Most importantly, this approach have certain drawbacks
associated with it: i) weak immunogenicity ii) tumors can easily escape immune
recognition through antigenic loss or mutation, iii) limited subset of patients due to HLArestriction, and iv) poor ability to activate balanced CD8+ and CD4+ T cell response.
Whole tumor cells or tumor lysate-based vaccines:
Theoretically, whole tumor cells contain all relevant TAAs and, as such, have the
potential to elicit an effective anti-tumor immune response when administered in
conjunction with an appropriate immunomodulator. In principle, these vaccines can have
more advantages over the single-target approaches as it not only can target both different
and unknown antigens at the same time but also able to stimulate robust adaptive immune
responses due to availability of both MHC class I and class II epitopes.
In the last two decades, several different vaccines derived from whole tumor cells
or tumor lysate have been tested in both preclinical and clinic settings. In preclinical
settings, vaccination with whole tumor cells was shown to stimulate the immune response
through direct tumor-antigen presentation as well as prolonged release of TAAs that
allow for sufficient tumor-antigen uptake by host APCs and subsequent activation of
immune effector cells (20). Mice vaccinated with irradiated whole tumor cells in
combination with an adjuvant, and subsequently challenged with non-irradiated tumor
cells, were found to efficiently generate anti-tumor immune recall responses (21). In
clinical settings, OncoVAX (Vaccinogen), an autologous irradiated tumor cells-based
7

vaccine has shown over 20% reduction in risk of colon cancer progression in patients
compared to control groups. This efficacy was translated into improved overall survival
of patients (22). Reniale, an autologous tumor cell lysate-based vaccine against RCC
with adjuvant treatment showed greater benefits in patients with a higher risk. GV AX,
another vaccine composed of two irradiated prostate cancer cell lines LNCaP and PC-3,
has demonstrated some local immune responses in preclinical studies. Based on this
encouraging preclinical study, it was further tested in clinical trials. Despite these
encouraging immunological results, GV AX failed to meet the defined endpoint in two
phase III clinical trials.
However, despite containing all relevant TAAs and thus avoiding the problem of
identifying appropriate tumor antigens, the use of autologous tumor cells for cancer
vaccines also faces major limitations (23). In addition to the weak immunogenic nature of
unmodified autologous tumor cell-based vaccines, the lack of sufficient tumor mass for
vaccine preparation due to early detection as well as the inability to surgically access for
certain cancers represent other limitations. Although tumor cells may be cultured for an
extended time period to generate enough cells for vaccine preparation, the inability of
certain tumor cells to grow under culture conditions poses another problem. As an
alternative, allogeneic tumor cells have been used as a source of TAAs, which ideally
would be taken up by APCs and presented to autologous immune effector cells.
Potentially, this would provide a limitless source of TAAs through well established cell
lines. Although allogeneic tumor cell lines allow for standardized and large scale
production of potential cancer vaccines, such vaccines were demonstrated to direct the
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majority of the immune response towards the alloantigens, and not TAAs, due to
dominant antigenic competition, leading to inefficient anti-tumor immune responses (23).
DNA and RNA-based vaccines:
DNA-based vaccines formulated to encode TAAs and/or immunostimulatory
molecules to elicit an effective anti-tumor immune response have emerged as a safer and
advantageous alternative to gene therapy in both preclinical and clinical settings. In
preclinical studies, intradermal injection of mice transgenic for rat neu and HER-2/neu
homologue with rat neu cDNA in combination with plasmids encoding costimulatory
molecules CD80lCD86 and 4-1BBL resulted in the induction of both cellular and
humoral immune responses (24). Recently, several phase 1111 clinical trials have been
conducted with DNA vaccines targeting variety of TAAs such as PSA, PAP, gplOO,
CEA, HSP65 against prostate cancer (25), melanoma (26), colorectal cancer (27), and
head and neck carcinomas (28). In most of the cases, these trials showed very low
immunogenicity of TAAs. In another phase I clinical trial, Meian-AIMART-l DNA
plasmid vaccine in patients with stage IV melanoma was well tolerated and induced an
immune response. However, the vaccine did not induce regression of established disease
(29). Despite pre-clinical and very low clinical success, the development of clinically
successful naked DNA cancer vaccines faces major hurdles, such as the need for high
doses of plasmid DNA, inefficient delivery of the gene of interest, low expression
efficiency of the introduced gene, lack of vaccine efficacy, and finally safety concerns.
In recent years, mRNA-based cancer vaccines are also breaking the grounds and
are being used as an attractive immunotherapeutic approach against cancers (30, 31). The
advantage of utilizing this approach is primarily because of its safety as transfected
9

mRNA does not integrate into the host genome (32). The principle behind this approach
is that mRNA-based vaccine containing mRNA-coding TAA is transfected into DCs and
translated into proteins which further processed and loaded on MHC for its presentation,
thus activating an antigen-specific T cell response (33). Several clinical studies have been
conducted by employing mRNA-based vaccine approach against different cancers such
as prostate (34), RCC (35), ovarian (36), lung, breast (37), neuroblastoma (38) and
melanoma (39). A phase I clinical trial with PSA-mRNA-based vaccine was able to
increase PSA-specific CTL response against metastatic prostate cancer (40). In another
clinical trial, vaccine containing DCs transfecting with total RNA extracted from clear
cell carcinoma against metastatic RCC showed significant increase in tumor specific
CD4+ and CD8+ T cells with simultaneous decrease in Treg frequency (36).
Why vaccine fails:

As mentioned above, although all the vaccine approaches have demonstrated
efficacy in various preclinical studies, they have been either ineffective or demonstrated
limited efficacy in clinical settings. These strategies are mainly associated with lack of
specificity, inefficient delivery, safety concerns, labor intensive, costly, and in some cases
patient-customized which severely limits their broad clinical applications. Among all the
concerns, one of the major hurdles for the clinical success may be due to the lack of
tumor specific antigens (TSAs) and/or weak immunogenic nature of TAAs, usually
recognized by the immune system as self-antigen. Theoretically, TSAs, mostly composed
of mutant proteins, are the ideal target for cancer vaccines due to their specificity;
however, the major drawback of targeting TSAs is the uniqueness of these mutations to
each

tumor,

potentially leading

to

the
10

development

of patient

customized

immunotherapy. On the other hand, TAAs are commonly expressed on the tumors with
same histology and are shared among tumors of different origins. But one of the major
limitations associated with TAAs are their weak immunogenic nature due to the tolerance
of self -antigens. The next major obstacle for clinical success may include active immune
evasion mechanisms employed by progressing tumors. These obstacles may be overcome
by using potent adjuvants/immunomodulators that not only boost the existing immune
responses to the tumor in patients, but also generate new immune responses and, most
importantly, overcome the immune evasion mechanisms.
Why adjuvants are critical?

The term "adjuvant" was first proposed by Ramos in 1920s which originated from
the latin adjuvo means "to help".

Adjuvants, substances that traditionally added to

vaccines are used to enhance the magnitude, breadth, quality and longevity of the innate
system to increase or modify a subsequent adaptive immune response, with minimal
toxicity. Addition of adjuvants in the vaccine may substantially reduce the amount of
antigen and/or number of immunizations required for optimum immune response. That is
why, in the last several decades, adjuvants have been known to be a critical determinant
of the success or failure of a vaccine and Charlie Janeway famously described the nature
of adjuvants as "the immunologists dirty little secret".
In the year between 1920s-1930s, it was found that aluminum salts can improve
the immune response (41), thus Alum became the first vaccine adjuvant and until a year
ago it has been the only approved adjuvant in USA for human vaccines. Adjuvants are
necessary to boost the optimal immune response to weak antigens. Most importantly,
adjuvants are important to overcome various tolerance mechanisms and facilitate the
11

induction of CTL response that can traffic to and lyse tumor cells. In this regard, the
application of alum as adjuvant for cancer vaccines is limited (42) because alum-based
vaccines primarily induce effective Th2 responses (43) with minimal efficacy in eliciting
Thl immunity (44), which is necessary for the eradication of tumors. In this context, the
choice of adjuvants is critical. Adjuvants can affect the nature of the elicited immune
responses, such as Thl vs. Th2 responses, T cell vs. B cell responses, generation and
maintenance of immunological memory, and reversal of the immunoregulatory
mechanisms, such as Treg-mediated suppression and T cell anergy. As such, adjuvants
that modulate innate, adaptive, and regulatory immunity in favor of the generation of
effective anti-tumor immune responses may have the best efficacy. Of critical importance
is the development of adjuvants with safety profiles in humans. Therefore, the
development of effective therapeutic cancer vaccines for the clinic will require
adjuvants/immunomodulators that can efficiently stimulate innate and adaptive immune
responses as well as reverse/inhibit tumor-mediated immune suppressive mechanisms.
Adjuvants for therapeutic cancer vaccines:

In the last several years, despite the fact that adjuvants are the critical
determinants of the success or failure of the vaccines, there has been great deal of
pessimism regarding their use for the development of therapeutic cancer vaccines. This is
mainly due to the lack of full characterization of mechanistic insight and precise
knowledge of the constituents of many adjuvants until recently (45, 46). Some of the
recently tested vaccine formulations, like viral vectors, are designed to express their own
adjuvants while others, like peptide-based vaccines, do not and hence reqUlre coadministration of adjuvants for the induction of potent immune response.
12

For the several decades, the choice of adjuvants available for cancer vaccines has
been very limited, mostly or in part due to toxicity concerns raising significant regulatory
hurdles. In fact, only aluminum-salt based adjuvants have been used for human use in the
United States for decades until recently when combination of aluminum hydroxide with
monophosphoryl lipid A (MPLA) has been licensed. Approval of recombinant vaccines
against HPV and HBV, albeit in preventing setting, has provided a great hope for the
development of several adjuvants to augment the efficacy of the cancer vaccines. As
oppose to adjuvants whose characterizations are poorly understood, a growing focus has
been shifting towards the use of natural ligands or synthetic agonists for well-defined
PRRs as adjuvants. Among all PRRs, toll-like receptors (TLRs) are the largest and most
well characterized family of a diverse set of germ line-encoded receptors which recognize
broad classes of conserved molecular structures common to groups of microorganisms
(47-49).
Due to the critical role of TLR signaling on the innate, adaptive, and regulatory
arms of the immune systems, TLR agonists have emerged as ideal adjuvants for cancer
immunotherapy. Perhaps addition of various TLR agonists to vaccine formulations has
been one of the most significant developments in the area of cancer vaccine. These
agonists include TLR-3 (poly I:C), TLR-4 (MPL), TLR-5 (flagellin), TLR-7 (Aldara),
TLR-7/8 (Resiquimod), and TLR-9 (CpG). Either alone or with various formulations,
these TLR agonists have been shown to enhance the vaccine efficacy. In case of
preclinical studies, these agonists have been demonstrated to generate anti-tumor
immunity by enhancing innate immunity through the activation of DCs, NK cells,
monocytes, and macrophages and induction of cytokines with both direct and indirect
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anti-tumor activity.

Engagement of TLRs on APCs, such as DCs, results in their

maturation and migration to lymph nodes where they initiate adaptive immune responses
and generate long-lasting memory against tumors. In case of clinical studies, MPLA has
already been licensed in United States by FDA and used as a component of Melacine,
Cervarix, a preventive HPV vaccine by GlaxoSmithKline Biological (GSK) (50), and is
also a component of NSCLC vaccine in late-stage clinical trials. RC-529 (GSK,
DynaVax), another synthetic TLR-4 agonist has been licensed for an HBV vaccine in
Europe (51). CpG oligodeoxynucleotides (ODN) has also shown great promise as an
adjuvant for TAA-based cancer vaccines (52).
Despite some promising clinical results, safety profile of these TLR agonists has
been of the major hurdles which need to be addressed for the use of these agonists as a
component of vaccine formulations. TLR agonists as components of vaccines have been
found to be associated with severe toxicity, resulting from non-specific activation of
lymphocytes and plausibly from signaling into non-immune cells (53-55). The limited
effect of TLR-signaling on the induction of adaptive immunity, which is critical to the
establishment of long-term immunological memory and prevention of tumor recurrences,
have also been one of the major challenges for these agonists to be used as an adjuvant
component of therapeutic cancer vaccines (56-58). Most importantly, TLR-signaling has
been found to be involved in the generation of regulatory immunity which plays a critical
role in immune evasion and allow tumors to counterbalance the anti-tumor immunity. For
example, TLR-4 signaling has been found to expand Tregs ex vivo and induce IL-IO
producing CD4+ Tregs in vivo (54). Similarly, CpG, a TLR-9 agonist was involved in the
conversion of CD4+ T effector cells into Tregs via plasmacytoid DCs (59), and was
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found to induce CDI9+ dendritic cells to acquire potent T cell suppressive functions
through the production of indoleamine 2,3-dioxygenase (60). Based on above discussed
outcomes, there is a dire need for the discovery and development of alternative adjuvants
which not only has the potent immunomodulatory activities on cells of innate, adaptive,
and regulatory immunity but also provides safety without significant toxicity at
therapeutic doses.

Costimulatory 4-1BBL and OX40L as a platform for the development oftherapeutic
cancer vaccines:
An effective therapeutic cancer vaccine should aim to generate anti-tumor

immunity by targeting T cells, APCs, and NK cells to eliminate the existing tumors and
to promote immunological memory that prevents the recurrences. Most importantly,
therapeutic cancer vaccine should also ideally prevent the generation and/or function of
Tregs. In this context, costimulatory molecules ofTNFR super-families play critical roles
in modulating innate, adaptive, and regulatory immune responses. Several preclinical
studies have demonstrated the effectiveness of agonists that express the extracellular
functional domain of TNF ligands and cross-link their costimulatory receptors for
effective signal transduction (61,62).
In recent years, there have been growing interests in two costimulatory molecules,
4-1BB and OX40, which are shown to function primarily on CD8+ and CD4+ T cells,
respectively. It is well known that signaling through 4-1BB and OX40 induces very
similar responses although not identical. OX40 is expressed early after CD4+ T cell
activation and mediates the effector T cells differentiation (63). Similarly, stimulation of
4-1BB induces very identical effects on CD8+ T cells (64). Nevertheless, signaling
15

through these two costimulatory pathways have shown to overlap in their effects on both
CD4+ and CD8+ T cells (65, 66). Agonistic ligands to these costimulatory receptors have
been, either alone or in combination, widely tested as effective adjuvants of therapeutic
cancer vaccines in both preclinical and clinical settings (62, 67). OX40 ligation has been
shown to induce T cell mediated antitumor responses against variety of tumors including
sarcoma, colon, breast, and prostate cancer (62, 68, 69). On the other hand, 4-1BB
ligation has shown effects on DC activation, survival, cytokines such as IL-6 and IL-12
which results into robust T cell stimulation (70, 71). Most importantly, 4-1BB ligation
renders T effector cells resistant to suppression by Tregs (15) while OX40 directly
inhibits the Tregs suppression (72). These agonistic antibodies induce robust
amplification of T cell mediated immune responses, inhibit apoptotic cell death (73, 74)
and stimulate long-lived T cell responses (75). In most of the studies, the anti-tumor
responses generated by these agonists are associated with increased activity of CD8+ and
CD4+ T effector functions. However, the biggest drawback with the use of agonistic
antibodies for costimulatory molecules lies in their involvement in the induction of severe
toxicity. These toxicities primarily arise from nonspecific, and systemic activation of
lymphocytes (76, 77). These toxicities have further shown to be associated with cytokinemediated disruption of lymphocyte trafficking, splenomegaly, multifocal hepatitis, and
lyphodenopathy (78, 79). Additionally, immunization of agonistic anti-CD28 monoclonal
Ab has found to be lethal due to systemic inflammatory responses in a phase I clinical
trial (80). Therefore, utilization of agonistic Abs as a component of therapeutic vaccines
requires a rigorous scrutiny due to its potential toxicity in humans and demands the
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development of agonists that provide appropriate immune signal transduction in the
absence of toxicity.
In this context, recently we have proposed the utilization of natural ligands as an
alternative to agonistic Abs that may have both qualitative and quantitative differences in
the generation of potent immune signal transduction with superior therapeutic efficacy in
the absence of severe toxicity. Due to limitation of these ligands to be functional only as
membrane bound proteins, not in soluble form, we have previously generated a chimeric
4-1BB ligand (SA-4-IBBL) by fusing its functional extracellular domain to a modified
form of core streptavidin (SA) for potent signal transduction. Due to virtue of SA, this
chimeric protein exists in stable tetramers and higher structures and allows this ligand for
the generation of potent immunological activities in soluble forms. The activity of this
natural SA-4-1BBL has already been established in our lab (81) and has been
demonstrated to be superior to agonistic anti-4-1BB Ab (3H3) in terms of qualitative and
quantitative differences (79). SA-4-1BBL in combination with both E7 peptide and
protein (TAA)-based vaccines demonstrated potent efficacy by eradicating> 70% of E7expressing TC-l tumors (15, 16). Based on our previous observations, we sought to
determine if SA-4-1BBL can be utilized as a successful vaccine adjuvant in other tumor
model with different TAA and if efficacy of SA-4-1BBL based vaccine can further be
improved by addition of another immunemodulator in the vaccine formulation.
Therefore, the first major goal of this Ph.D. dissertation was to test the therapeutic
efficacy of SA-4-1BBL in combination with survivin (SVN), a bona fide self-TAA in
3LL lung carcinoma model and determine the mechanistic insight of vaccine efficacy.
The second goal was to determine the efficacy of SA-4-1BBL in combination with
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another immunomodulator such as TLR-4 agonist MPLA and costimulatory SA-OX40L,
due to their distinct mode of action, in different preclinical tumor mice models.
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CHAPTER 2
SA-4-1BBL AS AN ADJUVANT COMPONENT OF A VACCINE CONTAINING
RECOMBINANT SURVIVIN INDUCES POTENT ANTI-TUMOR EFFICACY IN
A CDS+ T CELL AND NK CELL DEPENDENT MANNER

Introduction
Cancer remains one of the deadliest diseases despite progress in the discovery of
various strategies with the limited effects. The limited efficacy of these current treatment
modalities are often due to their association with adverse side effects arising from lack of
specificity for tumors, and most importantly their failure of eliminating residual and
micrometastatic tumors, which can lead to recurrences (1). In this scenario, therapeutic
vaccines based on tumor associated antigens (TAAs) are preferred alternatives to these
conventional treatments for cancer primarily because of their safety profile and
generation of long-term immunologic memory critical for the control of recurrences,
which are the main cause of death from cancer. In order to succeed, vaccination against
TAAs requires targeting the right TAA. The main properties of an ideal target TAA
should be: i) over-expressed in tumors but little or undetectable in normal tissues, ii)
essential for the survival of the tumors so that tumor immune escape can be avoided, and
iii) expressed in many tumors so that vaccine could target variety of cancers. In this
context, survivin (SVN) is known as one of the very few candidate TAAs that meet all
these criteria (82).
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SVN is a 16.5kD protein which is the smallest member of the inhibitor of
apoptosis proteins (lAP) family. It is involved in the suppression of apoptotic cell death
along with the regulation of cell division (82). SVN is expressed transiently in normal
cells while constitutively expressed in most human cancers and its over-expression
correlates with tumor progression and constitutes a poor patients survival (83, 84). It is
now known that SVN can generate cellular immune response as several SVN-derived
peptide epitopes that stimulate major histocompatability complex (MHC) class I
restricted cytotoxic T lymphocytes (CTLs) have been identified in both cancer patients
and in tumor-bearing mice (85-87). Since SVN-specific CTLs were able to target the
tumor cells, it is suggested that potential tolerance to self-antigen can be effectively
overcome and SVN-based immunotherapy can further be exploited in the clinic.
However, the development of successful therapeutic vaccines based on SVN has
not been fully realized as they have failed to mount an optimal clinical effect in a broad
patient population. The efficacy of such vaccines is curtailed by the weak antigenic
nature of SVN due to its potential immune tolerance to dominant epitopes and various
immune evasion mechanisms employed by the progressing tumors. To overcome these
limitations, therapeutic vaccine formulations containing SVN requires the inclusion of
potent adjuvants that not only generate robust immune responses with long-term
immunological memory, but also overcome various immune evasion mechanisms. In this
context, we recently hypothesized that costimulatory ligands, particularly 4-1BBL can be
exploited as potential adjuvant of choice for the development of therapeutic cancer
vaccines as it plays a crucial role in the generation and maintenance of CD8+ T cell
responses which is critical for the eradication of tumors (15, 16).
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4-1BBL is known as one of the most potent costimulatory ligand of tumor
necrosis factor (TNF) family due to its pleiotropic effects on variety of cells of innate
(71), adaptive (88) and regulatory immunity (89). Inasmuch as 4-1BBL is a cell surface
membranous protein and has no function in soluble form, recently we generated a
chimeric protein, from hereafter called as SA-4-1BBL, by fusing the extracellular
functional domain of 4-1BBL to a modified form of core streptavidin (SA). This soluble
SA-4-1BBL has shown potent immune activity as an adjuvant component ofTAA-based
vaccines by targeting various cells of innate, such as Des, NK cells, and adaptive, such
as CD4+ and CD8+ T cells, in various preclinical tumor models (15, 16). Most
importantly, SA-4-1 BBL also modulates regulatory immunity by reversing tumor
induced clonal anergy, renders T effector cells resistant to suppression by
CD4+CD25+FoxP3+ regulatory T cells, and inhibits the conversion of T effector cells
into Tregs through the production ofIFN-y.
We hypothesized that SA-4-1BBL can be exploited for the development of
therapeutic vaccines by targeting SVN self-TAA expressed by most of the tumors. Here
we report that single vaccination with SVN+SA-4-IBBL based vaccine resulted in the
significant eradication of SVN expressing 3LL tumor. The efficacy of vaccine was
mainly dependent on CD8+ T cells and NK cells effector function but not on the CD4+ T
cells. This efficacy was further improved to complete tumor eradication when an
additional vaccination was administered 6 days after the first vaccination. This improved
efficacy was correlated with increased level of IFN-y and cytotoxicity. Additionally,
SVN+SA-4-1BBL based vaccine also generate an effective humoral response without a
sign of autoimmunity. These results provide the mechanistic insight of SVN+SA-4-1 BBL
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vaccine in 3LL tumor model and emphasize the critical role ofCD8+ T cells and NK cells
in the vaccine efficacy. These observations also demonstrate the utility of additional
vaccinations for the optimal efficacy of self-TAA-based vaccine strategy that can target
variety of tumors and can successfully be translated into clinic.

Materials and Methods
Mice and cell lines

C57BLl6 and C57BLl6.SJL mice were purchased from The Jackson Laboratory,
Taconic, or bred in our barrier animal facility at the University of Louisville. All animals
were cared for in accordance with institutional and National Institutes of Health (NIH)
guidelines. The 3LL, TC-l and A20 cell lines were purchased from American Type
Culture Collection (Manassas, VA).
Cloning, expression, and purification of recombinant SVN

Mouse-cDNA was sub cloned into the pTWIN-I-6X-His bacterial expression
vector (New England Biolabs) using Nde I and BamH I restriction sites. After
transformation into C2566 competent E. coli cells (New England Biolabs), cultures were
grown at 37°C and induced using IPTG. Cells were harvested 3 h after induction,
pelleted, and resuspended in 100 ml of lysis buffer (2OmM Tris, pH 7.0, 500mM NaCl,
5mM imidazole, 5mM

~-ME,

IOIlM ZnC12). Cells were lysed by ultrasonication and

inclusion bodies and insoluble material were pelleted at 10,000xg for 10 min. Pellet was
washed three times by resuspending in lysis buffer containing 1% Triton X-I 00, rotating
30 min at room temperature, and repelleting at 35,000xg for 30 min. The final pellet was
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resuspended in 100 ml lysis buffer containing 6M Guanidine-HCI and rotated at RT
overnight to solubilize inclusion bodies. After, centrifugation at 35,000xg for 30 min at 4
°C to remove the insoluble material, supernatant collected for IMAC purification using
Talon® cobalt resin according to the manufacturer's protocol (Clontech) with the
exception of including 0.1 % Triton X-114 to remove endotoxin. All purification steps
were performed in the presence of 10JlM ZnCl2 and 5mM

~-ME

to assist with proper

folding and reduce oligomerization. Protein was dialyzed against PBS, concentrated
using an Amicon Ultra MWCO 10,000 and sterile filtered using a 0.22Jlm filtration
device. Protein concentration was measured using BCA and Bradford methods (Pierce).
Construction, expression, purification, and characterization of SA-4-1BBL have been
previously described (15). All the proteins had undetectable levels of endotoxin (SVN =
0.066 EU/Jlg protein, SA-4-1BBL=0.004 EU/Jlg protein).

Tumor models and immunizations
C57BLl6 mice were inoculated s.c with 1x105 live 3LL cells into the right flank.
For therapy, mice were vaccinated s.c. on day 6 post-tumor challenge with either SVN
protein (50 Jlg) alone or with SA-4-1BBL (25 Jlg). For the two vaccination therapy,
booster was administered either 3 days or 6 days or 9 days after first vaccination. Tumor
size was measured with caliper twice a week. Tumor progression was determined by
survival of mice which was defined when either tumor reached a size of 12 mm in
diameter or when tumors ulcerated or mice showed signs of discomfort, at which point
they were euthanized.

Intracellular cytokine assay
For intracellular cytokine staining, lymph node cells were resuspended in MLR
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medium at 2x106/ml and stimulated with PMA (5 ng/ml, Sigma) and ionomycin (500
ng/ml, Sigma) for 2 hrs in a 37°C, 5% CO2 incubator. GolgiPlug (1 J,ll/ml, BD
PharMingen) was added to the activation mixture and cells were incubated for an
additional 4 hrs. Cells were then stained with anti-CD44-APC and anti-CD8-APC-Cy7,
fixed with 4% paraforrnaldehyde, and stained with anti-IFN-y-PE-Cy7 or isotype
controls. FACS Caliber or LSR-II (BD Bioscience) was used for FACS acquisition
followed by data analysis using CellQuest (BD Biosciences), FlowJo (Tree Star), and
Diva (BD Biosciences) software.

In vitro CTL and NK cells killing assays
For in vitro cytotoxicity assay, long-term tumor free animals from SVN alone and
SVN+SA-4-1BBL groups were boosted and one week post vaccination, spleen was
harvested and splenocytes were cultured with 10J,lg SVN protein per ml in complete
MLR medium supplemented with 50 IU/ml of IL-2. Five days post culture; viable
lymphocytes (effector cells) were recovered by centrifugation over a Ficoll gradient.
Effector cells were then collected and tested for cytotoxic activity against eH]-thymidine
labeled 3LL tumor target for CTL killing and YAC-l tumor target for NK cell killing,
respectively at various Effector/Target (E:T) for 4 h.

In vitro lymphocyte proliferation
Splenocytes from naive and long term boosted mice were cultured (2x 105/ well)
with 5 jlg/ml of soluble SVN protein for 5 days in complete MLR medium. Cultures
were pulsed with eH]-thymidine for the last 16 hrs of the culture period, and harvested
on a Tomtec Harvester 96 (Tomtec Inc., Harnden, CT) for quantification of incorporated
radioactivity. Results were expressed as mean ± SD cpm of triplicate wells.
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Depletion assay
A depleting Ab

against mouse CD8+ T cells (500uglmouse, Clone 53.6.72,

Bioexpress), NK1.1 (500uglmouse, Clone PK 136, Bioexpress), and CD4+ T cells
(300uglmouse, Clone GK1.5, Bioexpress) were used via intra peritoneal injection to
deplete CD8+ T cells, NK cells and CD4+ T cells one day before vaccination. The
depletion of these cells was complete as monitored at day 5 post treatment.
Detection of antibodies
Anti-SVN antibody was detected in mouse sera using enzyme-linked
immunosorbent assay (ELISA). In brief 50 ng of SVN was coated on a 96-well plate by
overnight incubation at 4

0c. Plate was washed and blocked followed by incubation with

serum samples for 1.5 hrs at room temperature. Plate was washed and incubated with
anti-mouse IgG conjugated with horseradish peroxidase (HRP) for 1 hr followed by
incubation with substrate for 20 min. Reaction was stopped by sulfuric acid and measured
on spectrophotometer at 490 nm.
For autoantibody detection against ssDNA, ELISA was performed. In brief, plate
was coated with 1J.lglwell of heat-denatured calf thymus DNA (ssDNA, from Sigma).
Plate was washed twice followed by blocking with buffer containing 5% BSA + 0.5%
Tween 20 + 0.1 % nalve B6 serum. Serum dilution was added to the plate followed by
incubation at 4 DC for overnight. Plate was washed 3 times followed by addition of anti
mouse IgG-HRP and absorbance was measured at 450nm.
Statistics
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Statistical analyses were perfonned using the One Way Anova, and KaplanMayer curves test using SPSS software. For each test, P values have been displayed and
less than 0.05 and 0.001 were considered significant (*) and very significant (**),
respectively.

Results
Expression and purification of recombinant SVN
We generated plasmid encoding the pTWIN-1 expression vector, which contains
mouse SVN cDNA and 6X-His residues at C-tenninus (Fig. 1A). The recombinant SVN
was expressed in bacteria as inclusion bodies, denatured with Guanidine-HCI, and
purified using IMAC taking advantage of a C-tenninus 6X-His tag. The purified protein
runs approximately as a 16.5 kDa band on SDS-PAGE (Fig. 1B top panel) and reacts
with SVN antibody when analyzed on western blot (Fig. 1B bottom panel).
Next we tested if the 3LL cell line we are planning to use for this study expresses
SVN. We looked at the expression of SVN in both cell lysate and supernatant from 3LL
cell line along with other tumor cell lines like TC-1 and A20. As shown in Figure 2, cell
lysate from all the cell line scored positive for SVN (Fig. 2A) while we did not see SVN
expression in supernatant for either cell lines (Fig. 2B). These observations are consistent
with SVN being a universal TAA.
Single vaccination with SVN+SA-4-1BBL eradicated 3LL tumor and this efficacy
was primarily dependent on CDS+ T cells with partial involvement of NK cells
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First we evaluated the therapeutic efficacy of SVN+SA-4-1BBL vaccine in 3LL
tumor model. C57BLl6 mice were challenged s.c. with 1x105 live 3LL cells and
vaccinated once with either SVN alone (50

~g)

or with SA-4-1BBL (25

~g)

six days

post-tumor challenge. Tumor growth and lifespan of the mice were followed for over a
90-day period. As shown in Figure. 3, SVN+SA-4-1BBL vaccine was able to eradicate
tumors in approximately 70% of mice while efficacy of SVN alone could only reach to <
20%. In contrast, all PBS control mice were expired within 60 days.
The therapeutic efficacy of the vaccine was associated with robust CD8+ T cells, NK
cells effector and T cell proliferative responses
One of the major reasons for the failure of current tested SVN-based vaccines in
the clinic is due to their limited ability to mount optimal CD8+ T cells effector response
on a broad patient population. The importance of T cell in the successful therapy can be
deduced from this fact that the strategies which augment T cell effector responses to
weak tumor antigens can only be translated into effective therapy (90). Therefore we
evaluated the impact of SVN+SA-4-1BBL vaccine on CD8+ T cells effector response by
measuring the IFN-y in the long-term tumor free animals one week after boosting with
SVN+SA-4-1BBL. As shown in Figure 4A, long-term mice subjected to SVN+SA-41BBL vaccine had significantly enhanced number of CD8+ T cells expressing IFN-y as
compared to naIve mice, which translated into a robust SVN-specific CTL killing
response against 3LL targets (Fig. 4B).
As we (unpublished data) and others have already demonstrated that 3LL cells
acquire low level ofMHC class I (91, 92) as a means to escape CTL and survive. As cells
missing or low expression of MHC class I molecules lose resistance to NK cells and
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become susceptible to NK cell-mediated lysis (93, 94), we next tested the role of NK
cells on vaccine efficacy. We performed the NK cell specific killing assay against YAC-1
targets and observed a significant higher killing at all E:T ratios in mice subjected to
SVN+SA-4-1BBL as compared with naIve mice (Fig. SA).
We also tested if long-term animals are able to generate T cell proliferation
response after SVN exposure. To determine SVN-specific proliferation response,
splenocytes from naive and long term boosted mice were cultured in the presence of
soluble SVN protein for S days. As shown in Fig. SB, long-term boosted mice generated
significantly higher SVN protein-specific in vitro lymphoproliferative response as
compared with naIve animals.
Taken together, these data suggest the requirement of both CD8+ T cells and NK
cells for the success ofSVN+SA-4-1BBL based therapeutic effects.
CDS+ T cells are critical while NK cells also play an important role in the efficacy of
SVN+SA-4-1BBL vaccine

As SVN+SA-4-1BBL vaccine was able to generate potent CD8+ T cells effector
response with moderate NK cell killing response, which correlated with the therapeutic
efficacy, we next depleted these cells to evaluate the direct involvement of these cells in
the efficacy of vaccine. As shown in Figure 6, depletion of CD8+ T cells completely
abrogated the efficacy of the vaccine as all CD8+ T cells depleted animals died before day
SO due to tumor burden or discomfort. NK cells were also found to be a key player in the
efficacy of vaccine as depletion of NK 1.1 attenuated the survival of the mice from 80%
to 40%. We did not find any involvement of CD4+ T cells as depletion of these cells did
not affect the efficacy of the vaccine.
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Additional vaccination improved the therapeutic efficacy of the vaccine and this
efficacy was dependent on the timing of the vaccine
We next evaluated if additional vaccine will further improve the therapeutic
efficacy of the vaccine. Therefore, we boosted the animals with SVN alone or SVN+SA4-1BBL at various time points. As shown in Figure 7A, an additional booster of
SVN+SA-4-1BBL on day 12 (6 days after first vaccination) improved the survival of the
mice to 100% while SVN alone could improve the efficacy to only 25%. Interestingly,
the timing of booster was critical to vaccine efficacy as booster on day 9 and day 15
could not improve the survival benefit over one vaccination (Fig. 7B). Although we
observed attenuated therapeutic efficacy of vaccine on day 9 booster than single
vaccination, it did not reach to a significant level.
Taken together, these data suggest that prime-boost regimen is required and
timing of the boost is critical for the optimal SVN+SA-4-1BBL vaccine efficacy in 3LL
model system.

Improved efficacy with additional vaccination was associated with CDS+ T cells
effector function, but not the NK cells
Our earlier data of in vivo depletion (Fig. 6) demonstrated the critical role of
CDS+ T cell in the therapeutic efficacy of the SVN+SA-4-1 BBL vaccine. Therefore, we
next evaluated the mechanistic basis of this therapeutic advantage of additional booster
by measuring the CDS+ T cell effector responses. As shown, this therapeutic advantage
was strictly due to increased CDS+ IFN-'t T cell (Fig. SA) and cytotoxic responses (Fig.
SB), while NK cell response was not changed when compared with one vaccination (Fig.
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SC). Taken together, these data suggest that additional vaccination enhance antitumor
immunity by increasing the CDS+ T cell effector function but not the NK cell response.
SVN+SA-4-1BBL-based vaccine generated humoral response without any sign of
autoimmunity

Recently, involvement of humoral immune response to tumor immunotherapy has
been widely appreciated (95, 96), especially after the approval ofHerceptin, an antibodybased vaccine, as a part of treatment regimen against Her2 expressing breast cancer.
Therefore, we further investigated if SVN+SA-4-IBBL vaccine could also augment the
humoral response. Sera from vaccinated mice were analyzed for titer to SVN-specific
antibody. As shown in Figure 9A, SA-4-IBBL mediated co stimulation triggered the
humoral response when compared with SVN alone.
We also evaluated the effect of SVN+SA-4-IBBL vaccine on sign of
autoimmunity as one of the major issues with the utility of self-antigens is the induction
of autoimmunity which could be detrimental to the patients. Therefore, we tested the
presence of autoantibody in the sera of vaccinated mice. As shown in Figure 9B, SVNSA-4-1 BBL vaccine did not generate antibody against ssDNA as compared to sera from
lupus animals as a positive control.

Discussion

The efficacy of TAA-based therapeutic vaccine depends on the utility of
immunogenic antigens and potent adjuvants which increase the breadth and intensity of
the immune response of the vaccine. In the present study, we provide the evidence of
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mechanistic role of the SVN+SA-4-1 BBL vaccine and demonstrate that two vaccination
of this novel tumor vaccine results in the 100% survival of mice against 3LL tumors. This
level of efficacy, to our knowledge, has never been achieved before with SVN. The
efficacy of vaccine is associated with CD8 and NK cell effector functions. Physical
depletion of CD8, CD4, and NK cells suggests that CD8+ T cells are the most critical
player in the vaccine efficacy while NK cells also have an important contribution but not
the CD4+ T cells. Importantly, the efficacy of vaccine is dependent on the timing of the
treatment. SVN+SA-4-1BBL also generate a potent humoral response without any sign
of autoimmunity.
In recent years, TAA-based therapeutic vaccines have emerged as one of the most
attractive approach for the treatment of cancers. In this context, SVN has been
extensively used as an ideal TAA target for immunotherapeutic approaches due to its
high levels of expression in most of the cancers with potential clinical applications. Overexpression of SVN correlates with tumor progression and constitutes a poor patients
survival (83, 84). In fact the advantage of utilization of SVN for vaccine development is
not only relying on its broad expression patterns on majority of tumors, but also on the
fact that down-regulation or loss of its expression would hamper the tumor progression
and/or enhance the tumor cell death. These virtues make SVN based immunotherapy an
ideal approach to treat variety of cancers. However, the development of successful
therapeutic vaccines based on SVN self-antigen has been very limited in terms of tumor
eradication. In this regard, utilization of effective adjuvant as a part of vaccine
formulation holds great importance for the vaccine success.

Recently, we have

demonstrated that costimulatory ligand SA-4-1BBL can be exploited as potential
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adjuvant of choice for the development of therapeutic cancer vaccines against TC-1
tumors (15, 16). Consistent with our previous study, here we demonstrate that SVN in
conjunction with SA-4-1BBL costimulatory adjuvant resulted into an impressive efficacy
in the eradication of 3 LL tumors in > 70% of mice while efficacy with SVN alone could
reach to < 20%. The better efficacy of SVN+SA-4-1BBL was correlated with increased
CD8+ T cells IFN-y response which resulted into the higher CTL and NK cell killing
responses against 3LL and YAC-1 tumor cells, respectively.
Our results further show that an additional booster vaccination improves the
efficacy ofSVN+SA-4-1BBL vaccine from 70% to 100% in this model. Importantly, this
improved efficacy of additional booster was correlated with increased CD8+ IFN-y+ T
cells response and CTL cytotoxicity. Physical depletion of CD8+ T cells completely
abrogated the therapeutic efficacy directly confirmed the critical role of CD8+ T cells in
the vaccine efficacy in this model system. One of the major reasons for the failure of
current tested SVN-based vaccines in the clinic is due to their limited ability to mount
optimal CD8+ T cells response on a broad patient population. The importance of T cell in
the successful therapy can be deduced from this fact that the strategies which augment T
cell responses to weak tumor antigens can only be translated into effective therapy (90).

In this regard, SVN+SA-4-1BBL vaccine utilized in this study has shown great promise
due to virtue of SA-4-1BBL as it targets CD8+ T cell effector function which translates
into an effective therapy (15). Role of CD8+ T cells generated by SVN+SA-4-1BBL
vaccine in our study is in the agreement with several other reports which suggest that T
cells mounts a vigorous cytotoxic response against survivin both in vitro and in vivo (97,
98). Additionally, Xiang et al. (87) has also demonstrated that survivin-based DNA
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vaccine induces potent antitumor response against Lewis Lung Carcinoma and efficacy
of vaccine was dependent on antigen-specific CD8+ T cell response which triggered
tumor cell apoptosis, together with release of IFN-y. SVN+SA-4-IBBL vaccination also
enhanced the memory response evaluated by the increased SVN-specific T cell
proliferation in the long-term animals suggested that vaccine has potential to check the
recurrences.
We next observed that vaccine was also able to generate NK cell killing against
Y AC-1 target cells. Depletion of NK cells reduced the efficacy from > 70% to 40%
further confirmed the involvement of NK cells in the efficacy of SVN+SA-4-IBBL
vaccine in this model which was found to be additional mode of vaccine action. As we
(unpublished data) and others have already demonstrated that 3LL cells acquire low level
of MHC class I (91, 92) as a means to escape CTL and survive. Cells missing or low
expression of MHC class I molecules lose resistance to NK cells and become susceptible
to NK cell-mediated lysis (93, 94). This is consistent with the previous reports by several
groups demonstrating the crucial role NK cells play in killing of class I negative tumors
(99).
Next our results show that timing of the additional booster vaccination is critical
for the optimal vaccine efficacy. We administered the additional booster vaccination at
different time points after the first vaccination and to our surprise, we found out that
additional booster given 6 days after first vaccination was only able to improve the
efficacy of vaccine while booster on 3 days or 9 days after first vaccine didn't affect the
vaccine efficacy. This suggests that timing of the booster is critical for the optimal
efficacy. Surprisingly, booster on 3 days (early) after first vaccination relatively, although
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not significantly, lower the therapeutic efficacy of the vaccine when compared to single
vaccination. Recently, it has been reported that, depending on the timing of the treatment,
anti-4-1BB Ab can either cause activation-induced cell death (AICD) or enhance
immunity in viral setting (100). When given early after infection, anti-4-1BB was
immunosuppressive and associated with depletion of virus-specific CD8+ T cells while at
the later time points; the CD8+ T cell response was augmented.
One of the major concerns for self-TAA based immunotherapy is the potential
autoimmune abnormalities. Next we demonstrate that SVN+SA-4-1BBL vaccine did not
generate any sign of autoimmunity as we couldn't detect any autoantibody against
ssDNA in the sera of the mice treated with vaccine. However, we detected higher SVNspecific antibodies (humoral response) in the mice subjected to SVN+SA-4-1BBL
vaccine. Although generation of anti-SVN antibodies following therapeutic immunization
is currently not being seen as one of the predominant aspects of potential antitumor
response, existence of circulating antibodies against SVN has already been reported in
variety of human cancers (101, 102). Therefore, presence of these SVN-specific
antibodies in the cancer patients may predict as a means of host defense against tumors.
In this perspective, generation of SVN-specific humoral response by our vaccine may be
advantageous from the therapeutic point of view.
In conclusion, the vaccine strategy proposed in this study stand a chance of
translating into the clinics as the operational approach employed in this study along with
virtue of general applicability of our vaccine as a potent means of immunotherapy,
provides a rational for the further development of future therapeutic strategy against
cancer.
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Figure 1

Production of recombinant mouse-Survivin. (A) Schematic representation of pTWIN-l
expression vector with SVN, (B) Coomassie blue staining (top) and western blot (bottom)
patterns ofIMAC purified recombinant SVN.
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from TC-l, 3LL and A20 cell lines were prepared and analyzed using western blot.
Expression ofSVN was detected by anti-SVN Ab.
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Figure 6
Efficacy of SVN+SA-4-lBBL based vaccine is mainly dependent on CDS+ T cells
followed by NK cells but not on CD4+ T cells. The role of CDS+ T cells and NK cells in
the efficacy of vaccine was evaluated by depleting these cells with single i.p. injection of
anti-CDS (500 11 g), anti-CD4 (300 Ilg) and anti-NK1.1 (500 Ilg) Abs/mouse one day
before vaccination. The depletion of these cells was complete as monitored at day 5 post
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(This experiment was performed in collaboration with Rajesh Sharma).
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Figure 7
Additional vaccination of SVN+SA-4-1 BBL completely eradicates the tumor and this
improved efficacy is dependent on the timing of the booster. (A) C57BLl6 mice were
challenged with live lx10 5 3LL cells and vaccinated either once s.c. on day 6 or twice on
day 6 and day 12 post-tumor challenge with either SVN (50 llg) alone or with SA-41BBL (25 llg) (B) booster was also administered either 3 days or 9 days after the first
vaccination.

**

controls while

P < 0.001 for SVN+SA-4-1BBL two vaccine vs. SVN alone and PBS

* P < 0.05 for SVN+SA-4-1BBL two vaccine vs.

vaccine group. Data is pooled from two independent experiments.
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The increased therapeutic efficacy of booster vaccination is associated with improved
CD8+ T cells effector response but not the NK cells as demonstrated by (A) improved
CD8+ T cell intracellular IFN-'t expression, (B) increased CTL killing, but (C) no
difference in NK cell killing response. P values were calculated using student t-test.
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SVN+SA-4-1BBL based vaccme induced SVN-specific antibody without sign of
autoimmunityo (A) Sera from naIve (n=6) and long-term tumor free animals (n=6) were
tested for SVN-specific antibody using ELISA. (B) Sera from above animals were also
tested for autoantibodies against ssDNA. Sera from pooled (n=3) lupus animals were
used as positive control. P values were calculated using student t-test.
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CHAPTER 3
SA-4-1BBL AND OX40L COMBINATION AS AN ADJUVANT SYSTEM SHOWS
ROBUST THERAPEUTIC EFFICACY IN ESTABLISHED TC-l TUMORS
Introduction
One of the major advantages of utilization of vaccination strategy against cancers
IS

its ability to elicit an immune response to primary tumors and maintain an

immunological memory upon the reoccurrences. Given the most solid tumors usually
express MHC class I, but not MHC class II, role of CD8+ T cells in the eradication of
tumors attracted more attention than CD4+ T cells. However, it is critical to consider the
role of CD4+ T cells in the exertion of CD8+ T cell independent antitumor response as
well as the generation and persistence of memory CTL responses for designing the
vaccine against tumors. CD4+ T cells can induce antitumor immunity by recruiting and
activating macrophages and eosinophils and this effect can be independent of CD8+ T
cells (103, 104). CD4+ T cells generate IFN-y response which has antitumor or
anti angiogenic effects (105). In contrast, CD4+ T cells also help enhancing the antitumor
immunity of CD8+ T cells (l 06, 107). These above observations indicate the importance
of CD4+ T cells in tumor immunotherapy and justify the design of vaccines that aimed at
inducing a CD4+ T cell response for effective therapy.
We started this study based on our previous observations with E7+SA-4-1BBL
vaccine in TC-l tumor (16) and SVN+SA-4-1BBL vaccine (Chapter 2) in 3LL tumor
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which suggests the lack of CD4+ T cells involvement in the vaccine efficacy. These
findings could be interpreted as the inability of SA-4-1BBL-based vaccine to induce
CD4+ T cells response or that CD4+ T cells do not play any role in the vaccine efficacy.
We, therefore, addressed this issue by including an adjuvant with potent impact on CD4+
T cells in the SA-4-1BBL based vaccine formulation. In this regard, costimulatory
OX40L was the primary adjuvant of interest due to its critical role on the generation of
potent CD4+ T cell responses.
Recently, the costimulatory OX40, a member of tumor necrosis factor receptor
(TNFR) superfamily has been extensively studied as a potent antitumor agent. OX40 has
been shown to be expressed by CD4+ T cells and CD8+ T cells (67, 108). OX40 has been
widely studied on CD4+ T cells due to its high level expression after T cell activation.
Signaling via OX40 has shown increased migration, increased cytokine production by
effector cells, and increased numbers of CD4+ memory T cells (108-110). Agonistic
ligand to OX40 receptor has been widely tested as effective adjuvant of therapeutic
cancer vaccines in both preclinical and clinical settings.

Administration of

OX40Llimmunogiobulin fusion protein or OX40R mAb resulted in a significant
prolongation of survival of tumor-bearing mice (62). In most of the studies, the antitumor
responses generated by these agonists are associated with increased activity CD4 effector
functions. Most importantly, OX40 signaling directly inhibits the Tregs suppression (72)
makes it an attractive adjuvant for the development of therapeutic cancer vaccines.
Therefore, we hypothesize that by providing CD4+ T cells help and targeting Tregs via
OX40L will further enhance the antitumor efficacy of SA-4-1BBL vaccine which
primarily targets the CD8+ T cells (Fig. 10).
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In this study, we generated a novel fonn of OX40L by fusing the extracellular
functional domain of this molecule to a modified fonn of core streptavidin (SA) to
generate a chimeric molecule (SA-OX40L) that exists as tetramers and oligomers owing
to the structural features of SA. We here in show that this chimeric SA-OX40L has
preferential activity on CD4+ T cells in vitro while has activity on both CD4+ T cells and
CD8+ T cells in vivo.
Next, based on our previous observation of> 70% of therapeutic efficacy with
SVN+SA-4-1BBL vaccine, we sought to improve this efficacy by combining SA-41BBL with SA-OX40L which may further overcome the immune tolerance. A single
vaccination of SA-4-1BBL and SA-OX40L combination as a part of E7-based
therapeutic vaccine resulted into eradication of E7-expressing TC-1 tumors in 100%
mice. The efficacy of the combination vaccine is correlated with higher antigen specific
CD8+ T cell responses as compared to single agents. The combination vaccine was also
able to eradicate 3-4 mm size TC-1 tumors in 50% of the mice while single agent has
only 10% efficacy. Together, these data suggest that combination ofSA-4-1BBL and SAOX40L can be exploited to use as a new therapeutic vaccine strategy which has great
promise to be successful in the clinic.

Material and methods
Mice and cell lines

C57BLl6 and C57BLl6.SJL mIce were bred and maintained under specific
pathogen-free conditions in our barrier animal facility at the University of Louisville. All
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animals were cared for in accordance with institutional and NIH guidelines. TC-l cell
line was purchased from ATCC (Manassas, VA) and maintained as published (15, 111).
Antibodies and other reagents
Fluorochrome-conjugated anti-CD8-APC-Cy7, anti-CD62L-PE, anti-CD44-APC,
anti-TNF-PE, anti-IFN-y-PE-Cy7, and anti-IL-2-PerCp-Cy5.5, and isotype controls were
purchased from BD Bioscience, eBioscience, and BioLegend.

The HPV16

RAHYNIVTF E7 peptide (E749-57), SA-4-1BBL, E7, and SA proteins were reported
previously (15, 111)
Construction and expression of chimeric SA-OX40L protein
The extracellular functional domain of OX40L molecule was synthesized at
GenScript USA Inc. (Piscataway, NJ). The accurate sequence for OX40L was digested
with EcoRI and XhoI and subcloned into pMT-Bip-V5-HisA expression vector
containing a 6x-His Tag and core streptavidin (SA) sequence as previously published
(81). The chimeric SA-OX40L was expressed using Drosophila expression system (DES;
Invitrogen Life Technologies) followed by purification using IMAC Sepharose column,
endotoxin testing, and quantification.
Receptor Binding Assay
Receptor binding assay was performed as previously published (81). In brief,
splenocytes were stimulated with 5

~glml

Con A (Sigma-Aldrich) in complete MLR

media for 48 h. Naive or Con A activated splenocytes were then incubated with SAOX40L (200ngl106 cells) or molar equivalent of SA control protein on a shaker at 4
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°c

for 30 min. Following incubation, cell were washed extensively, stained with CD4-APC,
CD8-PercP and SA-FITC, and analyzed on flow.
T cell proliferation assay

Both CD4+ and CD8+ T cells were sorted from naive C57BLl6 mice and cultured
separately with 0.25 Jlglml anti-CD3 (BD Biosciences) and irradiated syngeneic
splenocytes in the presence of various concentrations of SA-OX40L or SA control
proteins. After four days, culture was pulsed with eH]thymidine during the last 16 h of
the culture and harvested on a Tomtec Harvester 96 for analysis.
For in vivo proliferation assay, OT-I and OT-II (CD45.2) cells were labeled with
2.5 JlM CFSE and 2x106 OT-I and OT-II cells were transferred by i.v. into naive
C57BLl6-SJL (CD45.1). After 24h, mice were immunized s.c with OVA (3 Jlg) alone or
with SA-4-1BBL (5 Jlg) or SA-OX40L (5 Jlg) or combination of both agents (5 Jlg+ 5
Jlg). After 3 days, peripheral LNs were harvested and OT-I and OT-II proliferation was
assessed by analyzing the CFSE dilution of CD45.2+CD8+ and CD45.2+CD4+ cells using
flowcytometry.
Tumor models and vaccination

C57BLl6 mice were subcutaneously (s.c.) challenged with 1x105 TC-1 cells into
the right flank followed by single s.c. vaccination on day 6 post-tumor challenge with
various vaccine formulations containing E7 protein (50 Jlg) alone as control or with SA4-1BBL (25 Jlg), SA-OX40L (25 Jlg), or the combination of both adjuvants (25
Jlgladjuvant). The diameters of tumors were measured with caliper and mice were
euthanized when tumor reached a size of 12 mm in diameter, ulcerated, or mice showed
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signs of discomfort. For depletion study, CDS+ and CD4+ T cells were depleted using
Abs against CDS (clone 53.6.72) and CD4 (clone GK 1.5) at 500 J..lg/mice via intra
peritoneal (i.p.) injection one day before vaccination.
For therapy with established tumors, mice with -3-4 mm TC-l tumors were
vaccinated with above described formulations twice at 5 days interval. Tumors were
followed for maximum of 100 days or until mice were euthanized due to tumor reached a
size of 12 mm in diameter, ulcerated, ormice showed any sign of discomforts.
Flow cytometry

Spleens and/or tumor draining lymph nodes (TdLNs) were processed as described
previously (16). For memory T cell typing, lymphocytes were stained with anti-CDSAPC-Cy7, anti-CD62L-FITC, and anti-CD44-APC Abs.

For intracellular cytokine

6

staining, lymphocytes (1xl0 cells/mL) were stimulated either with 10 J..lg/mL E749-57
peptide or whole E7 protein for 2 hrs followed by incubation with GolgiPlug (1 J..lllmL,
BD PharMingen) overnight. Cells were first stained with anti-CDS-APC-Cy7, anti-CD4Alexa700, and anti-CD44-APC, fixed with 4% paraformaldehyde followed by staining
with anti-IFN-y-PE-Cy7, anti-IL-2-Percp-Cy5.5, or isotype controls.

Results
Generation of chimeric SA-OX40L with demonstrated activity in soluble form

Under physiological conditions, cross-linking of costimulatory receptors by cell
membrane-bound ligands is critical for potent signal transduction and immune cell
activation. Due to this prerequisite, most of the costimulatory ligands have attenuated
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activity in the soluble fonn. Although agonistic Abs to these receptors is effective in
delivering immunological signals, we chose to use natural ligands since signals generated
by agonistic Abs is associated with severe toxicity (79). Based on our previously
constructed chimeric SA-4-1BBL molecule which has shown potent activity in the
soluble fonn in the absence of severe toxicity (15, 79, 81), we generated a chimeric SAOX40L costimulatory molecule due to its critical role on both effector and regulatory ann
of the immune system.
The extracellular domain of mouse OX40L, which is critical for binding and
delivery of immunological signals via its receptor OX40, was cloned C-tenninal to SA to
ensure proper protein folding as OX40L is a type II membrane protein (Fig. l1A). This
chimeric gene was then sub cloned into pMT-Bip-V5-HisA expression vector and
expressed using Drosophila expression system. As shown in Fig. 11 B, under native
condition SA-OX40L protein existed as tetramers and higher structures while under
native condition it existed as monomers, owing to the structural characteristics of SA
(Weber et al. Science, 1989). The chimeric SA-OX40L was able to bind OX40 receptor
expressing on both activate CD4+ and CD8+ T cells while binding to naive T cells was
undetectably low (Fig. 11 C).
Soluble SA-OX40L induce T cell proliferation
To evaluate the functional attributes of chimeric SA-OX40L in vitro, both sorted
CD4+ and CD8+ T cells were stimulated with suboptimal anti-CD3 Ab in the presence of
various concentrations of SA-OX40L. Costimulatory SA-OX40L was able to generate an
effective proliferative response in CD4+ T cells (Fig. 12A) but not in CD8+ T cells (Fig.
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12B). This response was both dose dependent and SA-OX40L specific as SA control
protein fail to generate any response.
We next tested the functionality ofSA-OX40L in vivo by utilizing OT-I and OTII system. As consistent with in vitro study, SA-OX40L generated a vigorous
proliferative response in CD4+ OT-II cells. On the other hand, just oppose to in vitro
study, SA-OX40L was able to generate CD8+ OT-I proliferative response in vivo but it
was not as robust as OT-II proliferation (Fig. 13).
Combination of SA-4-1BBL and SA-OX40L as the adjuvant component of E7 TAAbased vaccine completely eradicates the E7-expressing TC-l tumors
As previously reported, a single vaccination with E7+SA-4-1 BBL based vaccine
was able to eradicate E7-expressing established TC-l tumors in > 70% of mice and this
efficacy was preferentially due to the involvement of CD8+ T cell effector functions (16,
112). Keeping the aggressiveness of TC-l tumors and utilization of single adjuvant in
mind, this efficacy was turned out to be very impressive. Although, CD8+ T cells are very
critical for the elimination of tumors, involvement of CD4+ T cells help cannot be
ignored. Since 4-1BB signaling preferentially targets the CD8+ T cells, probably this
could be a possible reason our previously reported E7+SA-4-1BBL vaccine couldn't
reach to its optimal potential. Therefore, we hypothesize that whether the therapeutic
efficacy of this vaccine can further be improved by modifying the formulation to include
SA-OX40L as the second adjuvant with primary effect on the CD4+ T cells. A single s.c.
vaccination with E7 protein mixed with SA-4-1BBL and SA-OX40L resulted in the
eradication of TC-l tumors in all mice for 90 day observation period (Fig. 14). In
contrast, monotherapy with SA-4-1BBL and SA-OX40L resulted in eradication of tumor
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in only> 70% and > 60% of mice, respectively. Mice that expired from tumor in the
single agent groups, however, had slow kinetics of tumor progression as compared with
both PBS and E7 protein control groups where all mice expired from the tumor burden
around day 60 (Fig. 14). Taken together, these data demonstrate that combination of SA4-1BBL and SA-OX40L formulation is effective in eradicating the TC-1 tumors than the
individual agents.

The therapeutic efficacy of SA-4-1BBL and SA-OX40L combination is associated
with the CDS+ T cell effector and memory responses
CD8+ T cell effector and memory responses are the key mechanisms immune
system employ to eliminate the primary tumor and control the recurrences, respectively,
in various tumor settings, including the TC-1 model (16, 113, 114). We, therefore,
assessed the effect of combination vaccine on the CD8+ T cell effector and long-term
memory responses. Mice that had eradicated the tumor in response to various vaccine
formulations were boosted s.c. with the same formulations and intracellular cytokine
response of CD8+ T cells to the dominant E749-57 epitope was tested one week later (15).
In congruent with the therapeutic efficacy, combination of SA-4-1BBL and SA-OX40L
generated a better antigen-specific cytokine response than single adjuvant therapy as
assessed by CD8+ T cell expressing IFN-y single (Fig. 15A), and IFN-y IL-2 double
cytokines (Fig. 15B). There was no significant difference found between SA-4-1BBL
and SA-OX40L monotherapy at cytokine levels. Additionally, combination vaccine
formulation also generated the most effective CD8+ T cell memory recall responses as
compared to those including SA-4-1BBL and SA-OX40L as single agents (Fig. 15C).
Most importantly, combination vaccine was also able to significantly reduce the
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CD4+Foxp3+ Tregs in the spleen as compared to single agents (Fig. 15D). Combination
vaccine was also able to generate better CD4+ and CDS+ T cell proliferation response in
vivo as compared to single agents (Fig. 16). Collectively, these data demonstrate that

combination of SA-4-1BBL and SA-OX40L generate potent CD4+ and CDS+ T cell
proliferative and CDS+ T cell effector and memory responses that correlate with the
therapeutic efficacy of the vaccine against the TC-1 tumor.
CDS+ T cells are the most critical player followed by CD4+ T cells in the therapeutic
efficacy of both SA-OX40L+SA-4-1BBL combination therapy as well as SA-OX40L
monotherapy
Due to generation of CDS+ and CD4+ T cells responses by SA-4-1BBL and SAOX40L, we used Abs against CDS and CD4 molecules to deplete CDS+ and CD4+ T
cells, respectively. Mice with TC-1 tumors were treated with depleting Abs one day
before vaccination with E7 in conjunction with combination ofSA-OX40L+SA-4-1BBL
or SA-OX40L monotherapy. As shown in Fig. 17, depletion of CDS+ T cells almost
completely abrogated (100% vs. 16%) while depletion of CD4+ T cells also significantly
abrogated (100% vs. 40%) the therapeutic efficacy of SA-OX40L+SA-4-1BBL
combination therapy. Depletion of CDS+ T cells (66% vs. 20%) and CD4+ T cells (66%
vs. 33%) also significantly abrogated the efficacy of SA-OX40L monotherapy. Based on

our previous data, depletion of CDS+ T cells completely abrogated the efficacy of the SA4-1BBL monotherapy while CD4+ T cell depletion doesn't affect the efficacy (data not
shown). Taken together, these data provide direct involvement of both CDS+ and CD4+ T
cells in the therapeutic efficacy of combination as well as SA-OX40L mono therapies.
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Combination of SA-4-1BBL and SA-OX40L vaccine formulation eradicates the
established E7-expressing TC-l tumors
Next we tested if combination vaccine fonnulation is able to eradicate more
stringent established tumors. Mice with 3-4 mm size of TC-l tumors were vaccinated
twice on day 6 and day 12 with various vaccine fonnulations and followed for 100 days.
As we expected, combination vaccine fonnulation was even able to completely eradicate
3-4 mm TC-l tumors in 50% of mice (Fig. 18). In contrast, single agents were only able
to eradicate tumors in > 10% of mice while all control mice died within 60 days.

Discussion
In this study, we demonstrated that the chimeric SA-OX40L had potent activity
on both CD4+ and CD8+ T cells with preferential effects on CD4+ T cells in vivo. Next,
we demonstrated that addition of SA-OX40L in SA-4-lBBL vaccine fonnulation further
improved the efficacy of the vaccine to 100% in TC-l cervical cancer model. The
efficacy of combination therapy was associated with robust primary CD8+ T cell effector
and long-tenn memory as well as CD4+ T cell responses. Most importantly, the
combination vaccine was also able to eradicate the more stringent 3-4 mm large TC-l
tumors in 50% of mice.
The choice of addition of OX40L, another member of costimulatory TNF ligand
family, to SA-4-lBBL based vaccine was due to its potent effects on CD4+, CD8+ T and
Tregs with preferential influence on CD4+ T cells. As SA-4-lBBL primarily targets the
CD8+ T cells, attaining an additional CD4+ T cells help is expected to improve the
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therapeutic efficacy of the vaccine as CD4+ T cell help is essential for generation of
primary CD8+ T cell response (115, 116). We chose to generate SA-OX40L instead of
using already available agonistic anti-OX40 Ab due to qualitative and quantitative
differences between natural ligand and agonistic Abs (79). As we expected, the generated
chimeric SA-OX40L was able to induce potent CD4+ and CD8+ T cell proliferative
response with preferential effect on CD4+ T cells, which is consistent with previous
studies with anti-OX40 Abs. Most importantly, combination of SA-4-1BBL and SAOX40L was able to generate potent proliferative responses in both CD4+ OT-II and CD8+
OT-I cells in vivo. This efficacy further translated into a better therapeutic outcome
against established TC-l tumors.
The therapeutic outcome may be contributed by several mechanisms including
synergy between 4-lBB and OX40 signaling. Although 4-1BB co stimulation strongly
targets the CD8+ T cells while OX40 targets CD4+ T cells, there is considerable overlap
in their expression and functional mechanisms. Due to wide cellular distribution of these
two receptors, it may increase the possibility of potential targets and therefore, enhance
the chances of SA-4-lBBL and SA-OX40L to act on one or more cell types. It is likely
that CD8+ T cells are the common target for both the ligands as both the receptors are
reported to be expressed on CD8+ T cells following TCR signaling and enhance CD8+ T
cell response with the binding of agonistic mAbs, mostly via improved CD8+ T cell
effector function and their survival (67, 117). Therefore, dual costimulation through SA4-1BBL and SA-OX40L could enhance effector function of CD8+ T cells. Consistence
with this notion, we observed an improved effector CD8+ T cells response, as measured
by IFN-y and IL-2 double cytokines, in the mice subjected to SA-4-lBBL and SA-
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OX40L combination therapy when compared to single agents. Most importantly,
depletion of CD8+ T cells in the combination therapy almost completely abrogated the
vaccine efficacy suggested the critical role these cell population play in the combination
therapy.
The effect of SA-OX40L on combination therapy, an alternative to its direct
effect on CD8+ T cells, could also be due to its influence on promoting CD4+ T cells help.
Although previous reports has shown the null effect of CD4+ T cell help on the efficacy
of anti-4-1 BB and anti-OX40 mAbs combination therapy as depletion of CD4+ T cells
did not abrogate the efficacy (118), we observed the completely opposite result which
suggests the involvement of CD4+ T cell in vaccine efficacy. Physical depletion of CD4+
T cells in our model system significantly compromised the efficacy if SA-OX40L
monotherapy as well as combination of SA-4-1BBL and SA-OX40L combination
therapy, suggesting the influence of SA-OX40L on CD4+ T cells. This observation is in
congruence with our initial functional assays where SA-OX40L shows preferential
effects on CD4+ T cells.
Finally, both 4-1BB and OX40 expression have been reported on Tregs cell and
signaling via agonistic Abs and/or natural ligands to these receptors have been reported to
abrogate the Treg-mediated immunosupression (81, 119). Inhibition of Treg-mediated
suppression is one of the most critical phenomena required for therapeutic vaccine
efficacy. Consistence with this notion, we also observed the lower Treg numbers in
spleen of the mice subjected to combination therapy. Although the exact mechanistic
basis of effect of SA-4-1 BBL and SA-OX40L on the reduced number of Tregs observed
in our model is unknown, it is possible that SA-OX40L may preferentially induce
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apoptosis in Treg cells as previously reported (120) or SA-4-1BBL may block the
conversion of Teff cells into induced Tregs as supported by our unpublished data
demonstrating that SA-4-1BBL blocks tumor- and

TGF-~-induced

conversion of Teff

cells into induced Treg cells through IFN-y (Madireddi et aI., manuscript submitted).
In conclusion, regardless of potential mechanisms, our data strongly supports the
use of combination ofSA-4-1BBL and OX40L as the immunomodulatory components of
therapeutic vaccines against cancers with significant clinical potential.
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Figure 10
Hypothesis: Coordination between CD4+ and CD8+ T cells. SA-OX40L primarily targets
CD4+ T cells while SA-4-1BBL targets CD8+ T cells. SA-OX40L-mediated CD4+ T cells
further become either effector cells or help SA-4-1BBL-mediated CD8+ T cells effector
response for robust anti-tumor immunity. Additionally, both SA-OX40L and SA-4-1BBL
together reverse the Treg-mediated suppression either directly or indirectly, provide
additional critical support to antitumor immunity.
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Figure 11

Construction and characterization of SA-OX40L protein. The extracellular domain of
mouse OX40L was cloned C-terminal to core SA in the PMT/BiP/V5-HisA vector (A).
After sub-cloning, right size of OX40L band (lane 2) was shown by gel electrophoresis
(B). Binding of OX40L to OX40 receptor (C). Naive or ConA activated C57BLl6
splenocytes were incubated with SA-OX40L (200 ngllxl0 6 cells) or equimolar amount
of SA protein and binding of SA-OX40L on CD4+ (top panel) and CD8+ T cells (bottom
panel) was assessed by flow cytometry using anti-SA.
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Figure 12

SA-OX40L induces CD4+ T cell proliferation but not CD8+ T cell in vitro. CD4+ T cell
(A) and CD8+ T cell (B) proliferation. Flow purified CD4+ and CD8+ T cells were
stimulated for 48h with suboptimal dose of anti-CD3 Ab with various doses of SAOX40L in the presence of irradiated syngeneic splenocytes. Cells were pulsed with eH]thymidine for the last 16 h of culture. Data are representative of minimum of three
independent experiments.
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Figure 13

In vivo OT-I and OT-II cell proliferation in peripheral LNs. Two million OT-I and OT-II
T cells (CD45.2l each were labeled with CFSE and injected (i.v.) into congenic
C57BL/6.SJL (CD45.1 +) mice. Mice were vaccinated 24h later with either OVA (3 Ilg)
alone or in combination with SA-OX40L (5 Ilg). Proliferation of both OT-II (top panel)
and OT-I (bottom panel) was assessed using FACS caliber 3 days after vaccination by
gaiting on CD4+CD45.2+ and CD8+CD45.2+ cells. Data are representative of minimum of
three independent experiments.
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Figure 14
Combination of SA-4-1BBL and SA-OX40L completely eradicates the TC-l tumors.
C57BLl6 mice were challenged with lx105 live TC-l cells in the right flank and
vaccinated s.c. on day 6 post tumor challenge with either E7 alone (50 Jlg) or with SA-4IBBL (25 Jlg) or SA-OX40L (25 Jlg) or combination of both agents (25 Jlg + 25 Jlg).

< 0.05 for combination therapy vs. all other groups.
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Vaccination with the SA-4-1BBL+SA-OX40L induces strong multi-functional cytokine
and memory responses by CD8+ T cells, and reduces Treg percentage that correlates with
vaccine efficacy. Long-term (> 90 days) surviving mice were boosted with the same
indicated vaccine formulations used for primary vaccination. Lymph node cells were
harvested 7 days later and assessed for E749-57 peptide-specific CD8+ T cells expressing
intracellular IPN-y mono (A), IPN-yIL-2 double cytokines (B). Splenocytes from the
same groups

were phenotyped to test the percentage of effector memory

CD44hiCD62LlowCD8+ T cells (C) and CD4+Poxp3+ cells (D). Data for each panel are
representative of two independent experiments that include 3-4 mice per group. P values
were as shown and calculated using one way ANOVA and Tukey HSD test (ns
significant).
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Figure 16
Combination of SA-4-1BBL and SA-OX40L generates better OT-I and OT-II cell
proliferation in vivo. Two million OT-I and OT-II T cells (CD45.2+) each were labeled
with CFSE and injected (i.v.) into congenic C57BLl6.SJL (CD45.1 +) mice. Mice were
vaccinated 24h later with either OVA (3 /lg) alone or in combination with SA-OX40L (5
/lg) or SA-4-1BBL (5 /lg) or combination of both agents (5 /lg

+ 5 /lg). Proliferation of

both OT-II (top panel) and OT-I (bottom panel) was assessed using FACS caliber 3 days
after vaccination by gating on CD4+CD45.2+ and CD8+CD45.2+ cells. Data are
representative of minimum of three independent experiments. This figure also contains
partial data from figure 13.
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Figure 17

Therapeutic efficacy of SA-OX40L+SA-4-1BBL combination and SA-OX40L mono
therapies requires both CD8+ and CD4+ T cells. CD4+ and CD8+ T cells were depleted
using Abs against CD8 and CD4 molecules, respectively, one day before vaccination
with E7 TAA and the indicated vaccine formulations using the TC-l tumor model.

** P

< 0.001 for E7+SA-OX40L+SA-4-1BBL vs. CD4+ and CD8+ T cells depleted groups.
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Figure 18
Combination of SA-4-1BBL and SA-OX40L has robust therapeutic efficacy in
eradicating 3-4 mm established TC-1 tumors. C57BLl6 mice were challenged with 1x105
live TC-1 cells in the right flank. Once tumor size reaches 3-4 mm in size, mice were
vaccinated s.c. with either E7 alone (50 Ilg) or with SA-4-1BBL (25 Ilg) or SA-OX40L
(25 Ilg) or combination of both agents (25 Ilg + 25 Ilg) twice on day 5 and day 10, and
followed for 100 days.

** P < 0.001 for combination therapy vs. all other groups.
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CHAPTER 4
SA-4-1BBL AND MPL COMBINATION AS AN ADJUVANT SYSTEM SHOWS
ROBUST THERAPEUTIC EFFICACY BY INCREASING INTRATUMORAL

CDS+ T EFFECTORlCD4+Foxp3+ T REGULATORY CELL RATIO

Introduction

Therapeutic vaccines are preferred alternatives to conventional treatments for
cancer primarily because of their safety profile and generation of long-term
immunological memory critical for the control of recurrences, which are the main cause
of death from cancer. Therapeutic vaccines based on tumor associated antigens (TAAs)
are particularly attractive because of their ease of production, scale-up, storage, and
administration to a broad patient population. The efficacy of such vaccines, however, is
curtailed by the weak antigenic nature of self TAAs due to both central and peripheral
tolerogenic mechanisms (121, 122). These limitations can potentially be overcome by
developing vaccine formulations including adjuvants that not only generate potent
immune responses against TAAs with long-term immunological memory, but also
overcome various immune evasion mechanisms.
Recent advances in our understanding of the immune system, mechanistic basis of
immune activation, response, and establishment of long-term immunological memory,
and key molecules involved in regulating such responses have provided an unparalleled
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opportunity to design adjuvants with known molecular actions and desired activities for
the development of effective and safe therapeutic vaccines. Critical to the activation and
maintenance of an immune response are the signals transduced by toll-like receptor
(TLR) and costimulatory receptor pathways (123, 124). As such, agonistic ligands to
receptors of these two pathways have significant potential as adjuvants for therapeutic
vaccines. Consistent with this notion is the approval of TLR-4 agonist MPL, a nontoxic
version of lipopolysaccharide, by FDA to be used as the adjuvant component of a
preventive vaccine against HPV infection (125). However, the efficacy of MPL as the
adjuvant component of therapeutic vaccines against cancer remains to be demonstrated.
MPL primarily targets innate immunity, leading to the recruitment, activation, and
maturation of antigen presenting cells (APCs), such as DCs that facilitate the generation
of adaptive immune responses (126) (Fig. 19).
Unlike TLR pathway, costimulation directly targets adaptive immunity and is
critical for the generation of primary as well as memory T and B cell responses (124),
which led us to recently propose costimulatory ligands as potential adjuvants of choice
for the development of therapeutic cancer vaccines (111). In particular, we focused on 41BBL as the costimulatory member of TNF family because of the critical role of this
molecule in the generation and maintenance ofCD8+ T cell responses (127, 128) and the
importance ofCD8+ T cells in eradication of tumors (129, 130). Inasmuch as 4-1BBL is
a cell surface membranous protein and has no function in soluble form, we fused the
extracellular functional domain of this molecule to a modified form of core streptavidin
(SA) to generate a chimeric molecule (SA-4-1BBL) that exists as tetramers and
oligomers owing to the structural features of SA (112). SA-4-1BBL has potent immune
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· activity in soluble form and targets T effector (Teff) cells for activation, acquisition of
effector functions, and establishment of long-term memory that translate into robust
therapeutic efficacy in various preclinical models (111, 112, 131, 132).

Most

importantly, SA-4-1BBL also modulates regulatory immunity by reversmg tumor
induced

clonal

anergy,

rendering

Teff

cells

resistant

to

suppression

by

CD4+CD2S+FoxP3+ T regulatory (Treg) cells (111), and inhibiting the conversion of Teff
cells into Treg cells through the production of IFN-y (Madireddi et aI., manuscript
submitted). These combined effects results into better therapeutic efficacy in cancer
setting as compared with two TLR agonists, CpG and MPL (111).
Given that MPL primarily targets APCs , such as DCs and macrophages, for the
initiation of adaptive immunity (126) and 4-1 BBL targets CD8+ T cells for activation,
acquisition of effector function, survival, and long-term memory (133-135), and the
critical role of CD8+ T cells for tumor eradication (129, 130), we hypothesized that an
adjuvant system composed of both of these molecules may have potent therapeutic
efficacy as the component of TAA-based vaccine formulations against cancer (Fig. 20).
Consistent with this notion, a single vaccination with both adjuvants and E7 TAA
resulted in effective eradication of E7 expressing TC-I tumor in all mice. This effect was
extendable to the 3LL pulmonary lung carcinoma model where survivin (SVN) was used
as a bona fide self-TAA. The intratumoral CD8+ Teff/Treg cell ratio played a definitive
role in the efficacy of the vaccine, which was confirmed by the depletion of CD8+ Teff
and Treg cell populations. Taken together, these data demonstrate the utility combination
of SA-4-IBBL and MPL together as a novel adjuvant system for the development of
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therapeutic TAA-based subunit cancer vaccines which may have a significant clinical
potential.

Materials and Methods
Mice and cell lines
C57BLl6 and C57BLl6.SJL mice were bred in our barrier animal facility at the
University of Louisville. All animals were cared for in accordance with institutional and
NIH guidelines. TC-I and 3LL cell lines were purchased from ATCC (Manassas, VA)
and maintained as published (111).

Antibodies and other reagents
Fluorochrome-conjugated anti-CD8-APC-Cy7, anti-CD62L-PE, anti-CD44-APC,
anti-TNF-PE, anti-IFN-y-PE-Cy7, and anti-IL-2-PerCp-Cy5.5, and isotype controls were
purchased from BD Bioscience, eBioscience, and BioLegend. MPL was purchased from
InvivoGen (San Diego, CA). The HPVI6 RAHYNIVTF E7 peptide (E7 49-57), SA-4IBBL, E7 and mouse SVN proteins were reported previously (111).

Tumor models and vaccination
C57BLl6 mice were challenged subcutaneously (s.c.) with lxl0 5 live TC-I cells
into the right flank. For therapy, mice were vaccinated s.c. on day 6 post-tumor challenge
with various vaccine formulations containing E7 protein (50 Ilg) alone as control or with
SA-4-1 BBL (25 Ilg), MPLA (25 Ilg), or the combination of both agents (25 Ilglagent).
The doses ofE7, SA-4-IBBL, and MPL used in this study were based on our previously
published studies (111). Mice were euthanized when tumor reached a size of 12 mm in
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diameter, ulcerated, or mice showed signs of discomfort. CDS+ and CD4+ T cells were
depleted using Abs against CDS (clone 53.6.72) and CD4 (clone GK 1.5) at 500 Jlg/mice
via intra peritoneal injection one day before vaccination.
For the pulmonary tumor model, 2x10 s live 3LL cells were injected i.v. into the
tail vein of mice. Mice were vaccinated s.c. either once on day 6 or twice on days 6 and
12 post-tumor challenge with various vaccine formulations containing SVN protein (50
Jlg) alone as control or with SA-4-1BBL (25 Jlg), MPL (25 Jlg), or the combination of
both agents (25 Jlg/agent).

Mice were euthanized 27 days post-tumor challenge for

analysis of lung tumor burden as described (112, 136).
Flow cytometry and confocal microscopy
Spleens and/or tumor draining lymph nodes (TdLNs) were processed as described
previously (111). For memory T cell typing, lymphocytes were stained with anti-CDSAPC-Cy7, anti-CD62L-FITC, and anti-CD44-APC Abs.

For intracellular cytokine

staining, lymphocytes (lx106 cells/mL) were stimulated either with 10 Jlg/mL E749-S7
peptide for 2 hrs followed by incubation with GolgiPlug (1 JlI/mL, BD PharMingen)
overnight or with PMA (5 ng/ml, Sigma) and ionomycin (500 ng/ml, Sigma) for 2 hrs
followed by incubation with GolgiPlug (1 JlI/ml) for an additional 4 hrs. Cells were first
stained with anti-CD44-APC and anti-CDS-APC-Cy7, fixed with 4% paraformaldehyde,
and then stained with anti-IFN-y-PE-Cy7, anti-IL-2-Percp-Cy5.5, anti-TNF-PE, or
isotype controls followed by acquisition and analysis as previously reported (112).
Intratumoral CDS+ T cells and CD4+Foxp3+ Treg cells were analyzed using confocal
microscopy as described (112).
Analysis of autoantibody to ssDNA
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A ssDNA ELISA was perfonned to assess the presence of auto-Abs in treated
mice as described (137). Briefly, ninety six titer plates coated with 1 !Jglwell of heatdenatured calf thymus DNA (ssDNA, Sigma) were blocked with PBS containing 5%
BSA + 0.5% Tween 20 + 0.1 % naive C57BLl6 serum. Serum dilutions were added to
wells and incubated at 4°C overnight. Wells were washed 3 times, incubated with antimouse IgG-HRP, and absorbance was measured at 450 nm.

Results
Combined use of SA-4-1BBL and MPL as the adjuvant component of E7 TAAbased vaccine has robust efficacy in eradicating established TC-l tumors
We recently demonstrated that a single vaccination with SA-4-1BBL and E7
protein was effective in eradicating E7 expressing established TC-l tumors in > 70% of
mice (112). Although impressive, we sought to test whether the therapeutic efficacy of
this vaccine can further be improved by modifying the fonnulation to include MPL as the
second adjuvant with primary effect on the innate immunity (126, 138). A single s.c.
vaccination with E7 protein mixed with SA-4-1BBL and MPL resulted in the eradication
of established TC-l tumors in all mice, which remained tumor-free over an observation
period of 90 days (Fig. 2IA). In contrast, monotherapy with SA-4-1BBL and MPL
resulted in eradication of tumor in only 80% and 50% of mice, respectively. Mice that
expired from tumor in the single agent groups, however, had slow kinetics of tumor
progression as compared with both PBS and E7 protein control groups where all mice
expired from the tumor burden within 50 days (Fig. 21B). Taken together, these data
demonstrate that SA-4-1BBLlMPL as an adjuvant system is effective in eradicating the
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established TC-l tumors with better therapeutic efficacy than the individual agents, and
that SA-4-1BBL has better efficacy than MPL.

The therapeutic efficacy of the vaccine is associated with robust effects of SA-4IBBL and MPL on the generation of peripheral CDS+ T cell responses
CD8+ T cell effector and memory responses are critical to the elimination of
primary tumor and control of recurrences, respectively, in various tumor settings,
including the TC-l model (111, 129-131). We, therefore, assessed the CD8+ T cell
effector and long-term memory responses elicited by various vaccine formulations. Mice
that had eradicated the tumor in response to various vaccine formulations were boosted
s.c. with the same formulations and then euthanized one week later to test the
intracellular cytokine response of CD8+ T cells to the dominant E749-57 epitope (129).
Consistent with the therapeutic efficacy, vaccination with E7 protein and SA-4IBBLlMPL generated a better antigen-specific cytokine response than single adjuvant
therapy as assessed by CD8+ T cell expressing IL-2, IFN-y, and TNF-a triple cytokines
(Fig. 22A-C). Consistent with the therapeutic responses, mice vaccinated with SA-4IBBL formulation generated significantly (P < 0.05) better IFN-y response than the MPL
formulation (Fig. 22A). We also observed E7 TAA-specific TC-l killing (Fig. 23A)
responses in mice vaccinated with both adjuvants as compared with single adjuvants.
Consistent with the therapeutic efficacy, SA-4-1BBL as monotherapy generated better
killing responses than E7 antigen alone, whereas MPL failed to do so. Importantly,
vaccine formulation with the SA-4-1BBLlMPL also generated the most effective CD8+ T
cell memory recall responses as compared to those including SA-4-1BBL and MPL as
single agents (Fig. 23B). Collectively, these data demonstrate that SA-4-1BBL and MPL
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adjuvants work together to generate potent CD8+ T cell effector and memory responses
that correlate with the therapeutic efficacy of the vaccine against the TC-1 tumor.

Vaccination with the SA-4-1BBLIMPL adjuvant system results in a favorable
intratumoral CDS+ Teff/Treg cell ratio
Elevated levels of intratumoral CD4+Foxp3+ Treg cells along with a decline in
CD8+ Teff cells is associated with a clinically unfavorable prognosis of cancer patients
(139, 140) and depletion of Treg cells results in better immune efficacy of therapeutic
vaccines (141, 142). Therefore, we evaluated the effect of SA-4-1BBLlMPL adjuvant
system on the status of intratumoral Treg and Teff cells. Mice bearing

~3-4

mm TC-1

tumor were vaccinated s.c. with various vaccine formulations. One week postvaccination, tumors were harvested and analyzed for the presence of intratumoral CD8+ T
cells and CD4+FoxP3+ Treg cells using confocal microscopy. There was a significant
reduction in the number of intratumoral Treg cells in mice vaccinated with either SA-41BBL as a single adjuvant or in combination with MPL when compared with PBS
controls or E7 protein alone. (Fig. 24A top panel and B).

Interestingly, vaccine

formulation containing MPL as a single adjuvant did not have detectable effect on the
number of intratumoral Treg cells as compared with PBS control, and indeed performed
worse than E7 protein alone that appreciably, but not statistically significant, reduced the
intratumoral number of Treg cells.
We next tested if a decrease in the number of Treg cells caused by SA-41BBLlMPL or SA-4-1BBL as monotherapy inversely correlates with the number of
intratumoral CD8+ T cells, a hallmark of successful immunotherapeutic approach against
cancer (143). Vaccination with SA-4-1BBLlMPL had the most pronounced effect on the
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number of intratumoral CDS+ T cells infiltration followed by SA-4-1BBL, whereas MPL
had a moderate effect that was similar to the E7 protein alone (Fig. 24 A bottom panel
and C). This increased intratumoral CDS+ T cells by SA-4-1BBLIMPL resulted into the
most favorable intratumoral TeffiTreg cell ratio followed by SA-4-1BBL as monotherapy
(Fig. 24D).

In marked contrast, MPL as a single adjuvant had no effect on the

intratumoral Teff/Treg cell ratio as compared with both PBS and E7 protein controls.
Taken together, these findings demonstrate that SA-4-1BBL and MPL work in synergy to
increase the intratumoral TeffiTreg cell ratio that correlates with the potent efficacy of
this adjuvant system in eliminating established tumors.
CD8+ T cells are critical to the therapeutic efficacy of SA-4-1BBLIMPL adjuvant
system while Treg cells are detrimental to the efficacy of MPL monotherapy
To test if a high CDS+ Teff/Treg cell ratio can serve as a predictor of vaccine
therapeutic efficacy, we used Abs against CDS and CD4 molecules to deplete CDS+ Teff
and Treg cells, respectively.

Mice with established TC-l tumors were treated with

depleting Abs one day before vaccination with E7 protein admixed with SA-4IBBLlMPL or MPL as monotherapy. As shown in Figure 25, depletion of CDS+ T cells
completely abrogated the therapeutic efficacy of SA-4-1BBLlMPL adjuvant system,
while depletion of CD4+ T cells, including Treg cells, improved the therapeutic efficacy
of MPL from 50 to 100%. Taken together, these data provide direct evidence for the
opposing roles of CDS+ T and Treg cells in vaccine efficacy and point to the importance
of Teff/Treg cell ratio as a predictor of vaccine efficacy/failure.
Vaccination with SA-4-1BBLIMPL adjuvant system and SVN eradicates established
3LL pulmonary metastatic tumors
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The robust efficacy of vaccination with xenogeneic E7 T AA in combination with
SA-4-1BBLlMPL in eliminating TC-l tumors in all mice led us to test if this efficacy is
translatable to SVN as a weak and potentially tolerant self-TAA using the 3LL
pulmonary metastasis model. Mice were challenged i.v. with a lethal dose of live 3LL
cells followed by s.c. vaccination on day 6 with various formulations containing SVN
recombinant protein and SA-4-1BBL and/or MPL as adjuvants. As shown in Fig. 26A,
vaccine formulation containing both adjuvants had the most therapeutic efficacy over
single adjuvants in controlling tumor growth as demonstrated by both lung weight and
presence of tumor nodules. Similar to the TC-l model, vaccine formulation containing
SA-4-1BBL had better efficacy in controlling tumor growth than MPLA, which had
statistically significant (P < 0.05) effect in controlling tumor growth over PBS and SVN
alone controls. The therapeutic efficacy of SA-4-1BBLIMPL and SA-4-1BBL, but not
MPL, as monotherapy correlated with significantly (P < 0.05) higher number of CD8+ T
cells expressing IFN-y+ as compared with PBS and SVN alone controls (Fig. 26B).
Although lungs of SA-4-1BBLlMPL vaccinated mice had similar weights as
compared with lungs of naive mice, some of the lungs had microscopically detectable
tumor nodules. We therefore, tested the efficacy of a booster injection 7 days after the
first vaccination. As shown in Figure 27, boosting with SA-4-1BBLIMPL resulted in
complete eradication of lung tumor in all mice. Booster vaccination with single adjuvants
was also effective in eradicating and/or controlling tumor burden that reached statistical
significance (P <: 0.05) as compared with PBS and SVN alone controls. Collectively,
these findings further confirm the utility of SA-4-1BBLIMPL as a powerful adjuvant
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system to elicit potent immune responses to a self-TAA that translates into effective
immunotherapy in a stringent pulmonary preclinical metastasis model.

Therapeutic efficacy of the SA-4-1BBLIMPL adjuvant system is achieved in the
absence of detectable clinical toxicity and autoimmunity
Autoimmunity is a potential setback to effective self-TAA-based therapeutic
vaccine formulations using potent adjuvants to induce immune responses to such antigens
(144). Given the potent therapeutic activity of the adjuvant system used in this study, we
tested serum from mice with successful immunotherapy for both the TC-l as well as 3LL
models for the presence of Abs against ssDNA as a sign of systemic autoimmunity.
There was lack of significant amount of auto-Abs to ssDNA in all the groups tested,
whereas the serum from mice with full blown lupus had high levels of such Abs (Fig. 28).
Importantly, we did not detect signs of acute toxicity in vaccinated mice based on weight
loss, unexpected mortality, gross anatomy, and macroscopic analysis of body organs,
demonstrating the safety profile of this adjuvant system.

Discussion
In the present study, we tested if the costimulatory ligand SA-4-1BBL and TLR-4
agonist MPL with distinct mechanisms of action can serve as a novel adjuvant system for
the development of therapeutic TAA-based subunit cancer vaccines. MPL collaborated
with SA-4-1BBL as the adjuvant component ofHPV E7 TAA-based vaccine to generate
robust primary CD8+ T cell effector and long-term memory responses that translated into
improved therapeutic efficacy in the TC-l cervical cancer mouse model. The therapeutic
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efficacy of the adjuvant system was totally dependent on CD8+ T cells and associated
with a favorable intratumoral CD8+ TefflCD4+Foxp3+ Treg cell ratio. Importantly, the
therapeutic efficacy of the adjuvant system was not limited to the xenogeneic E7 TAA,
since a vaccine formulation containing SVN as a bona fide self-TAA was equally
effective in eradicating/controlling tumors in the 3LL metastatic pulmonary cancer
model.
The choice ofSA-4-1BBL and MPL as the adjuvant system is due to their distinct
mechanisms of action and targeting different immune cells for activation. MPL primarily
targets innate immunity by interacting with the constitutively expressed TLR-4 on DCs
and macrophages, leading to the production of various proinflammatory cytokines and
upregulation of various costimulatory and MHC molecules that altogether regulate
adaptive immune responses (126). SA-4-1BBL, on the other hand, interacts with the
inducibly expressed 4-1 BB receptor on both CD4+ and CD8+ T cells, leading to their
survival, expansion, acquisition of effector function, and long-term immune memory
(133-135). Importantly, 4-1BB signaling appears to have the most effect on CD8+ T
cells, which are critical to the eradication of tumors as demonstrated in various preclinical
settings, including the TC-l model (111, 129-131). Therefore, MPL in the adjuvant
system is expected to work with SA-4-1BBL for the activation of CD8+ T cells through
the activation of DCs and antigen cross-presentation (145), resulting in the upregulation
of 4-1 BB receptor on the surface of CD8+ T cells that in turn become the direct target of
SA-4-1BBL. This scheme is supported by our current findings that MPL collaborates
with SA-4-1BBL in generating robust CD8+ T cells primary and long-term memory
responses that translate into effective therapy in two different established tumor models,
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TC-l cervical and 3LL pulmonary carcinoma, with two different antigens, HPV E7
xenogeneic and SVN bona fide self-TAA antigens. Consistent with this notion, depletion
ofCD8+ T cells one day before vaccination completely abrogated the efficacy of the SA4-IBBLlMPL adjuvant system in eradicating TC-l tumors. In addition to its direct effect
on CD8+ T cells, SA-4-IBBL may also augment the effect ofMPL on DCs by improving
their antigen uptake and cross-presentation. This notion is supported by observations that
a subpopulation of DCs constitutively express 4-IBB receptor (146, 147), and
vaccination with SA-4-IBBL enhances their antigen uptake and cross-presentation (111,
112).
CD4+CD25+FoxP3+ Treg cells playa critical role in immune evasion mechanisms
employed by acute (148) as well as chronic infections (149, 150) and cancer (122, 141,
151), and as such serve as an important barrier for the efficacy of vaccines. Therefore,
vaccine formulations that specifically control the number and/or function of Treg cells
while enhancing the number of Teff cells may have desired therapeutic efficacy in
settings of cancer and chronic infections. Consistent with this notion are studies
demonstrating that the physical depletion of Treg cells or modulation of their regulatory
function using Abs to various cell surface markers have protective and therapeutic effects
against various tumors in preclinical models (151-155). Importantly, a recent study using
mice transgenically expressing the diphtheria toxin receptor only in Treg cells
demonstrated that specific and conditional depletion of these cells protected mice from
carcinogenesis induced spontaneous tumors via innate immunity and eradicated
established tumor via CD8+ T cell- and IFN-y-dependent responses (154). Consistent
with preclinical studies, Treg cells were shown to accumulate in various progressing
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cancers m patients and a high intratumoral Teff/Treg cells ratio is considered the
hallmark of a favorable prognosis (139-141). Important in this context, we found a robust
increase in the ratio of intratumoral CD8+ TeffiTreg cells in response to vaccination with
the SA-4-1BBLIMPL adjuvant system. Vaccination with SA-4-1BBL as monotherapy
also significantly improved the intratumoral CD8+ TeffiTreg cell ratio, which is
consistent with our recently published data (112). Surprisingly, MPL as monotherapy
was not only inefficient in significantly increasing the frequency of intratumoral CD8+ T
cell infiltration, but also failed to decrease the intratumoral number of Treg cells,
resulting in an unfavorable CD8+ Teff/Treg cell ratio. The Treg cells played a detrimental
role in the efficacy of MPL-based vaccine since their depletion one day before
vaccination resulted in eradication of all tumors (Fig. 25). This finding, to our knowledge
first, demonstrating that MPL efficacy is compromised by Treg cells is significant and
provides an important mechanistic insight in improving the efficacy of this FDA
approved adjuvant for the development of therapeutic cancer vaccines.
Although the primary targets of MPL are cells of innate immunity, a series of
recent studies have demonstrated that this adjuvant may also directly targets cells of
adaptive immunity. The expression of TLR-4 has been shown on CD4+ T effector and
Treg cells (156, 157). Importantly, stimulation via this receptor on CD4+ Teff cells was
shown to inhibit ERKII2 signaling pathway, resulting in the inhibition oftheir function in
an experimental colitis model (157). In marked contrast, stimulation of Treg cells with
the TLR-4 agonist lipopolysaccharide resulted in their survival, expansion, and improved
regulatory function in vivo (156), which may account for the unfavorable intratumoral
CD8+ TeffiTreg cell ratio seen in the MPL monotherapy group. Although the exact
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mechanistic basis of the synergistic effect of SA-4-1BBL and MPL on the intratumoral
CD8+ T/Treg cell ratio observed in our model is unknown, i) SA-4-1BBL may
preferentially induce apoptosis in Treg cells as reported for the agonists of OX-40
pathway (158), another close member ofTNFR costimulatory family, and/or ii) block the
tumor-mediated conversion of Teff cells into induced Treg cells, while iii) both agents
increasing the intratumoral frequency of CD8+ Teff cells, thereby favorably influencing
the CD8+ Teff/Treg cell ratio. This notion is supported by our unpublished data
demonstrating that SA-4-1BBL blocks tumor- and TGF-p-induced conversion of Teff
cells into induced Treg cells through IFN-y (Madireddi et aI., manuscript submitted). The
increased expression of IFN-y in response to SA-4-1 BBLlMPL adjuvant system in the
present study is further consistent with this notion. Importantly, although we observed
enhanced E7 TAA-specific frequency of CD8+ T cells expressing IFN-y in the periphery
of mice vaccinated with MPL as monotherapy, this effect did not result in increased
number of CD8+ T cells in the tumor, suggesting that these cells may not be trafficking
into the tumor. In contrast, vaccination with SA-4-1BBLlMPL adjuvant system resulted
in significantly higher numbers of CD8+ Teff cells both in the periphery and within the
tumor, suggesting that both adjuvants in combination may affect the trafficking/entry of
CD8+ Teff into the tumor and/or improve their survival.
Importantly, the therapeutic activity of SA-4-1BBLlMPL adjuvant system was
achieved in the absence of detectable acute toxicity and chronic autoimmunity. The lack
of acute toxicity is consistent with our previously published studies demonstrating that
treatment of mice with 4-fold higher SA-4-1BBL over the therapeutic dose used in this
study did not result in detectable toxicity as assessed by systemic cytokine response, non82

specific lymphoproliferation, altered lymphocyte trafficking, generalized lymphomegaly
and splenomegaly, and hepatitis, all of which were observed with similar doses of an
agonistic Ab to 4-1BB receptor (132). The safety ofMPL has already been demonstrated
both in preclinical and clinical settings (125, 126, 138).
In conclusion, the studies presented in this communication demonstrate the robust
efficacy of the SA-4-1BBLlMPL adjuvant system in inducing potent CD8+ Teffprimary
and long-term memory responses against TAAs and a favorable intratumoral CD8+
TefflTreg cell ratio that translate into potent therapeutic efficacy in two different tumor
models.

Importantly, the therapeutic efficacy of the vaccines was observed in the

absence of detectable acute toxicity or chronic autoimmunity. The better immune and
therapeutic efficacy of SA-4-1 BBLlMPL over MPL as monotherapy combined with MPL
being a clinically approved adjuvant (125) emphasizes the importance of further
developing this adjuvant system and assessing its efficacy as component of subunit
therapeutic vaccines against cancer and chronic infections.
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Targeting innate and adaptive immunity. Innate immune cells such as dendritic cell
engulf pathogens and present pathogen-derived peptide antigens to naIve T cells.
Additionally, TLRs recognize pathogen-derived components and induce expression of
costimulatory molecules and inflammatory cytokines. On the other hand, costimulatory
SA-4-1BBL also induce the dendritic cells activation and antigen cross- presentation.
Phagocytosis-mediated antigen presentation, TLR-mediated expression of co-stimulatory
molecules and inflammatory cytokines together with SA-4-1 BBL-mediated dendritic cell
activation and cross-presentation instruct development of antigen-specific adaptive
immunity, especially Thl cells.
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activation and cross-presentation instruct development of antigen-specific adaptive
immunity, especially Th1 cells.
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Figure 20

Hypothesis: Synergy between innate and adaptive immunity. MPL is recognized by TLR4 expressed on dendritic cells and induce expression of costimulatory molecule 4-1 BB
and inflammatory cytokines such as IL-12, IL-6, and TNF. On the other hand,
costimulatory SA-4-1 BBL also activates the dendritic cells by inducing CD80, CD86,
and CD40 expression and enhances antigen cross- presentation. MPL-mediated
expression of 4-1BB and inflammatory cytokines together with SA-4-1BBL-mediated
dendritic cell activation and cross-presentation instruct development of antigen-specific
adaptive immunity synergistically to target tumor cells. Additionally, combination of SA4-1BBL and MPL also targets the Tregs and MDSCs to avert their suppression on
effector cells. Take together, combination therapy targets all arm of the immune system
including innate, adaptive and regulatory.
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Figure 21
A single vaccination with the SA-4-1BBLIMPL adjuvant system results in the eradication
of established TC-l tumor in all mice. A, C57BLl6 mice were challenged s.c. with lxl05
live TC-l cells and left unvaccinated (PBS) or vaccinated once s.c. on day 6 post-tumor
challenge with E7 (50 Ilg) mixed with control SA protein (10 Ilg) or SA-4-1BBL (25 Ilg),
MPL (25 Ilg), or the combination of both agents (25 Ilg/agent). The log-rank test and
Kaplan-Meier method were used for analyses. *P < 0.05 as compared to all the other
groups, but SA-4-1BBL that was not significant (ns). B, Data from (A) are presented for
individual animals in each group.
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Figure 22
Vaccination with the SA-4-IBBLIMPL adjuvant system induces strong multi-functional
cytokine responses by CD8+ T cells that correlate with vaccine efficacy. Long-term (> 90
days) surviving mice were boosted with the same indicated vaccine formulations used for
primary vaccination. Lymph node cells were harvested 7 days later and assessed for
E749-57

peptide-specific' CD8+ T cells expressing intracellular IFN-y mono (A), IFN-

yTNF-a double (B), and IFN-yTNF-aIL-2 triple (C) cytokines. Data for each panel are
representative of two independent experiments that include 3-4 mice per group. P values
were as shown and calculated using one way ANOV A and Tukey HSD test (ns = not
significant).
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Figure 23

Vaccination with the SA-4-1BBLlMPL adjuvant system induces cytolytic and memory
responses that correlate with vaccine efficacy. Long-tenn (> 90 days) surviving mice
were boosted with the same indicated vaccine fonnulations used for primary vaccination.
A, Splenocytes were stimulated with E7 49-57 peptide and IL-2 for 5 days and used as
effectors against TC-l tumors. 3LL tumor cells were used as irrelevant targets B,
Splenocytes from the same groups were phenotyped to test the percentage of effector
memory CD44hiCD62LlowCD8+ T cells. Data for each panel are representative of two
independent experiments that include 3-4 mice per group. P values were as shown and
calculated using one way ANOVA and Tukey HSD test (ns = not significant).
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Figure 24

Vaccination with the SA-4-1BBLlMPL adjuvant system results in an increase in the
intratumoral Teff/Treg cells ratio. Mice bearing TC-l tumor (~3-4 mm in diameter; n = 4
per group) were vaccinated s.c. with E7 protein (50 J.1g) alone or with SA-4-1BBL (25
J.1g), MPL (25 J.1g), or a combination of both agents (25 J.1g/agent). One week postvaccination, tumors were harvested and stained for intratumoral CDS+ T cells and
CD4+Foxp3+ Treg cells followed by analysis using confocal microscopy. A, Confocal
pictures of tumor sections showing CD4+Foxp3+ Treg cells (top panel) stained with antiCD4 Ab (red), anti-Foxp3 Ab (green), and Hoechst (blue), and CDS+ T cells (bottom
panel) stained with anti-CDS Ab (red) and Hoechst (blue). Quantitative analysis of
intratumoral CD4+Foxp3+ Treg cells (B), CDS+ T cells (C), and CDS+ TeffiTreg cell ratio
(D). P values were as shown and calculated using one way ANOVA and Tukey HSD test
(ns = not significant).
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Figure 25
Therapeutic efficacy of SA-4-1BBLlMPL adjuvant system requires CDS+ T cells while
Treg cells compromise the efficacy of MPL monotherapy. CDS+ T cells and Treg cells
were depleted using Abs against CDS and CD4 molecules, respectively, one day before
vaccination with E7 TAA and the indicated adjuvant system using the TC-1 established
tumor model. Data for PBS, E7+MPL, and E7+MPL+SA-4-1BBL groups were taken
from Fig. 1.
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Figure 26

Vaccination with the SA-4-1BBLlMPL adjuvant system generates potent therapeutic
response in the 3LL lung metastasis model. Mice (n

=

4-5/group) were challenged with

2xl0 5 live 3LL cells by i.v. tail injection and vaccinated once s.c. on day 6 or twice on
days 6 and 13 post-tumor challenge with SVN (50 Ilg) alone or antigen with SA-4-1BBL
(25 Ilg), MPL (25 Ilg), or a combination of both agents (25 Ilglagent). A, Lungs were

harvested 27 days post tumor challenge and assessed for tumor growth by weight and
macroscopic presence of tumor nodules. B, Intracellular IFN-y response of CD8+ T cells
was assessed after PMA and ionomycin stimulation of splenocytes harvested from mice
in (A).
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Figure 27
Additional vaccination with SA-4-1BBLIMPL adjuvant system almost completely
eradicates the lung tumors. Lungs harvested from mice with two vaccinations are
assessed as in (Fig. 14). P values were as shown and calculated using one-way ANOVA
and Post Hoc LSD test (ns = not significant).
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Figure 28
Vaccination with the SA-4-1BBLlMPL adjuvant system does not promote autoimmunity.
Sera were harvested from mice challenged with 3LL tumor cells shown in Fig. 26 and
TC-l tumor cells in Fig. 21 A at the experimental end points and tested for the presence of
autoantibody against ssDNA in ELISA. Serum pooled from a minimum of 3 naive and 3
lupus mice were used as negative and positive controls, respectively.
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CHAPTER 5
CONCLUSIONS AND FUTURE PROSPECTIVES

The immune system has a potential to specifically recognize and eliminate cancer
cells without damaging normal healthy cells. As a result, therapeutic vaccination strategy
has been a promising approach to harness the immune system against disseminated
cancers. Among all, therapeutic cancer vaccines based on TAA presents an attractive
choice due to their safety profile, ease of production, storage, transportation,
administration to a broad patient population and most importantly establishment and/or
maintenance of long-term immunological memory critical for the control of recurrences.
However, the effectiveness of these vaccines will not only depend on their ability to
promote robust immune response but also overcome various immune evasion
mechanisms employed by progressing tumors. In this context, utilization of
immunomodulators which modulate the innate, adaptive, and regulatory immunity for
controlling the tumor progression will have better chance to succeed in clinic. Therefore,
utilization of SA-4-IBBL as a choice of adjuvant was a rational attempt due to its
pleiotropic effects on cells of innate, adaptive and regulatory immunity. In this project,
we first hypothesized that costimulatory SA-4-IBBL can be exploited to be a component
of successful therapeutic cancer vaccines in preclinical tumor models. We show that a
single vaccination of soluble form of SA-4-IBBL with SVN is able to eradicate SVNexpressing 3LL carcinoma in over 70% of mice without a sign of autoimmunity.
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During the last several years, there has been better understanding about the
suppressive mechanisms employed by progressing tumors that hampers the induction of
robust immune responses. These understandings have revealed new insight into how
suppressive cells such as Tregs and MDSCs could potentially be cleared or inhibited for
better therapeutic efficacy. In this regard, combination of diverse agents (combination
therapy) has shown a great potential against cancers due to their distinct mechanism of
actions. For example, combination of chemotherapeutic agents have been shown to
enhance cross-presentation leading to the augmentation of tumor-specific adaptive
immune response. Similarly, combination of adjuvants such a as TLRs that target
primarily innate immune response and stimulate Thl cytokines promote the efficiency of
T cell priming. Although an enormous efforts has been made in understanding the role of
combination therapy on tumor-immune interaction at both molecular and cellular levels,
clinical transitions is still in its infancy. But the development of effective cancer vaccines
received a great boost after a vast understanding of DC as well as effector/Treg biology
which clearly laid the ground for the development of improved clinical protocols. It is
now believed that rather than quantity, it is important to generate high quality and high
avidity polyclonal and poly-functional effector CD8+ T cells which are able to reject
tumors and long-lasting memory CD8+ T cells which are able to control recurrences.
Therefore, in this study, we attempted to utilize several combinatorial strategies that are
usually presented in discordant manner which set a platform for the development of
future therapeutic cancer vaccines. We here show that combination ofSA-OX40L+SA-4IBBL and SA-4-1BBL+MPL based therapeutic vaccine effectively enhanced polyfunctional CD8+ T effector cells. Combination SA-4-1BBL+MPL was also able to
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increase intratumoral CD8+ T effector/CD4+FoxP3+ T regulatory cell ratio. These all
mechanistic outcomes eventually translated into a complete eradication of tumors in both
TC-I

and 3LL tumor models. In last, this study also supports that future

immunotherapeutic cancer research should address multifunctional nature of the disease
using combination protocols.
The promising results from this overall Ph.D. study may provide a new avenue for
cancer vaccine immunotherapy. However, despite the exciting improvements in the
efficacy of various vaccine formulations studied in this study including tumor-free
survival, there is still much to determine about the immunological mechanisms by which
these results can be translated into the clinics. Additionally, it is also imperative to
improve our understanding of CTL activation, NK activation, decreased Treg numbers
and functionality, and impact of tumor escape.
In overall, these studies provide proof-of-principle data of the utilization SA-4IBBL alone or in combination with other immunomodulators (adjuvant systems) which
set a platform for clinical studies. Based on these studies, it is required to test the efficacy
of these adjuvant systems in more clinically relevant spontaneous tumor models with the
standard clinical practice. Eventually, testing these adjuvant systems in clinical trials will
assess the therapeutic potential of these adjuvant systems, and if proven efficacious in
therapeutic regimen, these adjuvant systems can be utilized against broad cancer types
with well defined TAAs.
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